New prognostic scoring system for primary myelofibro International Working Group for Myelofibrosis Researc

Blood

113, 2895-2901

DOI: 10.1182/blood-2008-07-170449

Citation Report

#	Article	IF	Citations
1	Facial Cosmetic Filler Injections as Possible Target for Systemic Sarcoidosis in Patients Treated with Interferon for Chronic Hepatitis C: Two Cases. Dermatology, 2008, 217, 81-84.	0.9	52
2	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy, 2009, 9, 663-670.	1.1	28
3	Philadelphia Chromosomeâ€“Negative Chronic Myeloproliferative Disease. American Journal of Clinical Pathology, 2009, 132, 261-280.	0.4	33
4	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opinion on Emerging Drugs, 2009, 14, 471-479.	1.0	19
5	Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Postâ€“Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 5587-5593.	0.8	117
6	Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. Journal of Cellular and Molecular Medicine, 2009, 13, 1437-1450.	1.6	23
7	Conventional cytogenetics in myelofibrosis: literature review and discussion. European Journal of Haematology, 2009, 82, 329-338.	1.1	107
8	Prognostic relevance of cytogenetic abnormalities in primary myelofibrosis: comparison of recent reports from Japan, the Mayo Clinic and MD Anderson Cancer Center. European Journal of Haematology, 2009, 83, 290-291.	1.1	1
9	Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosisâ€"increased serum ferritin or transfusion load does not. American Journal of Hematology, 2009, 84, 265-267.	2.0	66
10	Iron: The fifth horseman of the apocalypse?. American Journal of Hematology, 2009, 84, 263-264.	2.0	10
11	Prodromal myeloproliferative neoplasms: The 2008 WHO classification. American Journal of Hematology, 2010, 85, 62-69.	2.0	84
12	The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2010, 85, 141-142.	2.0	3
13	Transfusionâ€dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosisâ€"prognostic relevance is independent of IPSS or karyotype. American Journal of Hematology, 2010, 85, 14-17.	2.0	46
14	Coexistence of primary AL amyloidosis and POEMS syndrome: Efficacy of melphalanâ€dexamethasone and role of biochemical markers in monitoring the diseases course. American Journal of Hematology, 2010, 85, 131-132.	2.0	11
15	Prognosis and survivorship in primary myelofibrosis. American Journal of Hematology, 2010, 85, 4-5.	2.0	1
16	Deferasirox treatment may be associated with reversible renal Fanconi syndrome. American Journal of Hematology, 2010, 85, 132-134.	2.0	25
17	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. American Journal of Hematology, 2010, 85, 135-137.	2.0	3
18	Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasmsâ€"biologically plausible but clinically uncertain. American Journal of Hematology, 2010, 85, 93-94.	2.0	11

#	Article	IF	Citations
19	Diagnosis of chronic myeloproliferative neoplasms with special emphasis on early stages. Diagnostic Histopathology, 2009, 15, 125-133.	0.2	2
20	JAK2 Inhibitors: A Reality? A Hope?. Clinical Lymphoma and Myeloma, 2009, 9, S340-S345.	1.4	12
21	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. Advances in Hematology, 2009, 2009, 1-5.	0.6	14
22	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	0.6	196
23	Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: Evidence for Survival Gains in Recent Years. Mayo Clinic Proceedings, 2009, 84, 1114-1119.	1.4	27
24	The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood, 2009, 113, 4171-4178.	0.6	81
25	How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood, 2009, 113, 5394-5400.	0.6	100
26	Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood, 2009, 114, 5024-5033.	0.6	165
27	JAK2 kinase inhibitors and myeloproliferative disorders. Current Opinion in Hematology, 2010, 17, 110-116.	1.2	21
28	International Prognostic Scoring Systemâ€"independent cytogenetic risk categorization in primary myelofibrosis. Blood, 2010, 115, 496-499.	0.6	105
29	Comparison of prognostic scoring systems in primary myelofibrosis. Blood, 2010, 115, 745-745.	0.6	4
30	Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis. Blood, 2010, 115, 745-746.	0.6	0
31	Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood, 2010, 115, 4350-4355.	0.6	38
32	Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood, 2010, 115, 2719-2720.	0.6	6
33	Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood, 2010, 116, 4436-4438.	0.6	124
34	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 2010, 115, 1131-1136.	0.6	210
35	Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond. Blood, 2010, 115, 746-747.	0.6	9
36	Myeloproliferative Neoplasms: New Translational Therapies. Mount Sinai Journal of Medicine, 2010, 77, 667-683.	1.9	7

#	Article	IF	Citations
37	New Drugs for the Treatment of Myelofibrosis. Current Hematologic Malignancy Reports, 2010, 5, 15-21.	1.2	8
38	JAK2 Mutation and Thrombosis in the Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2010, 5, 22-28.	1.2	20
39	Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis. Current Hematologic Malignancy Reports, 2010, 5, 53-61.	1.2	11
40	Age and platelet count are IPSSâ€independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. European Journal of Haematology, 2010, 84, 105-108.	1.1	49
41	Treatment options for hydroxyureaâ€refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. European Journal of Haematology, 2010, 85, 192-199.	1.1	24
42	Chromosomal abnormalities in transformed Phâ€negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes and Cancer, 2010, 49, 919-927.	1.5	15
43	von Willebrand disease type 2N: Uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy. American Journal of Hematology, 2010, 85, 134-135.	2.0	0
44	Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. American Journal of Hematology, 2010, 85, 138-141.	2.0	8
45	Phase1/â€2 study of Pomalidomide in myelofibrosis. American Journal of Hematology, 2010, 85, 129-130.	2.0	77
46	Genetic polymorphisms in cytochrome P450s, GSTs, NATs, alcohol consumption and risk of nonâ€Hodgkin lymphoma. American Journal of Hematology, 2010, 85, 213-215.	2.0	2
47	ASH 2009 meeting reportâ€"Top 10 clinically oriented abstracts in myeloproliferative neoplasms. American Journal of Hematology, 2010, 85, 190-192.	2.0	0
48	ASH 2009 meeting reportâ€"Top 10 clinicallyâ€oriented abstracts in hematopoietic stem cell transplantation. American Journal of Hematology, 2010, 85, 193-196.	2.0	0
49	ASH 2009 meeting reportâ€"Top 10 clinically oriented abstracts in myelodysplastic syndromes. American Journal of Hematology, 2010, 85, 196-201.	2.0	0
50	ASH 2009 meeting reportâ€"Top 10 clinically oriented abstracts in coagulation medicine and platelet disorders. American Journal of Hematology, 2010, 85, 202-204.	2.0	0
51	ASH 2009 meeting reportâ€"Top 10 clinically oriented abstracts in sickle cell disease. American Journal of Hematology, 2010, 85, 204-206.	2.0	0
52	ASH 2009 meeting reportâ€"Top 10 clinically oriented abstracts in multiple myeloma. American Journal of Hematology, 2010, 85, 210-213.	2.0	0
53	ASH 2009 meeting report- the top 10 clinically-oriented abstracts in chronic lymphocytic leukemia (CLL). American Journal of Hematology, 2010, 85, NA-NA.	2.0	0
54	Stability of measurement of the immature platelet fraction. American Journal of Hematology, 2010, 85, 622-624.	2.0	24

#	Article	IF	Citations
55	Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization. American Journal of Hematology, 2010, 85, 611-613.	2.0	93
56	Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: Effect of sex, age, and geographical location. American Journal of Hematology, 2010, 85, 613-616.	2.0	59
57	Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin. American Journal of Hematology, 2010, 85, 624-626.	2.0	3
58	Iatrogenic immunodeficiencyâ€associated lymphoproliferative disease of the Hodgkin lymphomaâ€like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis. American Journal of Hematology, 2010, 85, 627-629.	2.0	10
59	Phase I/II study of singleâ€agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology, 2010, 85, 616-619.	2.0	18
60	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. American Journal of Hematology, 2010, 85, 619-622.	2.0	10
61	What do healthcare providers ask their patients with immune thrombocytopenia?. American Journal of Hematology, 2010, 85, 629-631.	2.0	1
62	Testicular lymphoma, intraocular (Vitreoretinal) lymphoma, and brain lymphoma: Involvement of three immunoprivileged sites in one patient. American Journal of Hematology, 2010, 85, 631-633.	2.0	12
63	Cardioprotective effect of metoprolol and enalapril in doxorubicinâ€treated lymphoma patients: A prospective, parallelâ€group, randomized, controlled study with 36â€month followâ€up. American Journal of Hematology, 2010, 85, 894-896.	2.0	177
64	Predicting survival for diffuse large Bâ€cell lymphoma patients using baseline neutrophil/lymphocyte ratio. American Journal of Hematology, 2010, 85, 896-899.	2.0	100
65	Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10â€year experience at single institution. American Journal of Hematology, 2010, 85, 904-907.	2.0	3
66	Comparison of real-time microvascular abnormalities in pediatric and adult sickle cell anemia patients. American Journal of Hematology, 2010, 85, 899-901.	2.0	32
67	Urinary markers of bone resorption, pyridinoline and deoxypyridinoline, are increased in sickle cell patients with further increments during painful crisis. American Journal of Hematology, 2010, 85, 902-904.	2.0	14
69	correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBCâ€“transfusionâ€dependence. British Journal of Haematology, 2010, 150, 719-721.	1.2	31
70	JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia, 2010, 24, 105-109.	3.3	109
71	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia, 2010, 24, 1302-1309.	3.3	300
72	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia, 2010, 24, 1533-1537.	3.3	22
73	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 2010, 24, 1128-1138.	3.3	499

#	Article	IF	Citations
74	Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplantation, 2010, 45, 458-463.	1.3	141
75	Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplantation, 2010, 45, 419-421.	1.3	8
76	Myeloproliferative neoplasms. , 0, , 283-306.		0
77	Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Management and Research, 2010, , 219.	0.9	0
78	Leucemia mieloide crÃ´nica e outras doenÃ§as mieloproliferativas crÃ´nicas. Revista Brasileira De Hematologia E Hemoterapia, 2010, 32, 71-90.	0.7	2
79	OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE. Mediterranean Journal of Hematology and Infectious Diseases, 2010, 2, e2010010.	0.5	7
81	Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. Expert Review of Hematology, 2010, 3, 23-33.	1.0	3
82	Assessing New Therapies and Their Overall Impact in Myelofibrosis. Hematology American Society of Hematology Education Program, 2010, 2010, 115-121.	0.9	16
83	The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplantation, 2010, 45, 1587-1593.	1.3	64
84	Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis. Clinical Cancer Research, 2010, 16, 1988-1996.	3.2	39
85	Mutational analysis inBCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. Leukemia and Lymphoma, 2010, 51, 576-582.	0.6	11
86	Phase II Study of Sunitinib in Patients With Primary or Postâ€“Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 281-284.	0.2	8
87	Improved Outcomes Using Tacrolimus/Sirolimus for Graft-versus-Host Disease Prophylaxis with a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant as treatment of Myelofibrosis. Biology of Blood and Marrow Transplantation, 2010, 16, 281-286.	2.0	29
88	Outcome of Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2010, 16, 358-367.	2.0	245
89	Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation. Biology of Blood and Marrow Transplantation, 2010, 16, 555-559.	2.0	46
90	Primary Myelofibrosis and the Myeloproliferative Neoplasms. JAMA - Journal of the American Medical Association, 2010, 303, 2513.	3.8	19
91	Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New England Journal of Medicine, 2010, 363, 1117-1127.	13.9	1,046
92	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood, 2010, 116, 2857-2858.	0.6	153

#	Article	IF	Citations
93	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115, 1703-1708.	0.6	805
94	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	0.6	216
95	Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood, 2010, 116, 3572-3581.	0.6	107
96	DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology, 2011, 29, 392-397.	0.8	854
97	How I treat myelofibrosis. Blood, 2011, 117, 3494-3504.	0.6	115
98	Prognostic Factors and Models in Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S25-S27.	0.2	9
99	Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia, 2011, 25, 1834-1839.	3.3	59
100	JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Therapeutic Advances in Hematology, 2011, 2, 21-32.	1.1	82
101	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer Journal, 2011, 1, e7-e7.	2.8	13
102	New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opinion on Investigational Drugs, 2011, 20, 961-972.	1.9	20
103	Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncology, 2011, 7, 1035-1043.	1.1	41
104	Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?. Leukemia and Lymphoma, 2011, 52, 1178-1187.	0.6	13
105	BCR-ABL1â€"Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S37-S45.	0.2	24
106	Hepatic nodule: a case of primary myelofibrosis. BMJ Case Reports, 2011, 2011, bcr0520114220-bcr0520114220.	0.2	5
107	Janus kinase inhibitors. Current Opinion in Oncology, 2011, 23, 609-616.	1.1	31
108	Diagnostic and therapeutic guideline for myeloproliferative neoplasm. Journal of the Korean Medical Association, 2011, 54, 112.	0.1	5
109	Targeting myeloproliferative neoplasms with JAK inhibitors. Current Opinion in Hematology, 2011, 18, 105-110.	1.2	38
110	Advances in the understanding and management of primary myelofibrosis. Current Opinion in Oncology, 2011, 23, 665-671.	1.1	14

#	Article	IF	Citations
111	Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood, 2011, 117, 5612-5615.	0.6	62
112	Recombinant interferon-Î± may retard progression of early primary myelofibrosis: a preliminary report. Blood, 2011, 117, 6669-6672.	0.6	122
113	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	0.6	280
114	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	0.6	144
115	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	0.6	242
116	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica, 2011, 96, 454-458.	1.7	65
117	Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica, 2011, 96, 167-170.	1.7	60
118	Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis. Haematologica, 2011, 96, 8-10.	1.7	9
119	Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the SociÃ©tÃ© FranÃ§aise de Greffe de Moelle et de ThÃ©rapie Cellulaire (SFGMâ€TC). British Journal of Haematology, 2011, 152, 331-339.	1.2	104
120	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60â€“78â€ƒyears of age. British Journal of Haematology, 2011, 153, 76-82.	1.2	51
121	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Reviews Drug Discovery, 2011, 10, 127-140.	21.5	261
122	Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia, 2011, 25, 82-88.	3.3	173
123	JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia, 2011, 25, 218-225.	3.3	117
124	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	0.8	724
125	Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies. Journal of Clinical Oncology, 2011, 29, 573-582.	0.8	272
126	Progression of myeloproliferative neoplasms to myelofibrosis and acute leukaemia. Journal of Hematopathology, 2011, 4, 61-68.	0.2	17
127	Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clinical Epigenetics, 2011, 2, 197-212.	1.8	36
128	Philadelphia-negative myeloproliferative Neoplasien. Wiener Klinische Wochenschrift Education, 2011, 6, 35-48.	0.0	0

#	Article	IF	Citations
129	Future Therapies for the Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2011, 6, 22-27.	1.2	6
130	ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. American Journal of Hematology, 2011, 86, 72-75.	2.0	33
131	Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). American Journal of Hematology, 2011, 86, 79-80.	2.0	5
132	Pain management in children and adolescents with sickle cell disease. American Journal of Hematology, 2011, 86, 82-84.	2.0	22
133	Multiple myeloma and pregnancy. American Journal of Hematology, 2011, 86, 81-82.	2.0	16
134	Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. American Journal of Hematology, 2011, 86, 87-89.	2.0	57
135	Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. American Journal of Hematology, 2011, 86, 85-87.	2.0	50
136	Activation of mononuclear phagocytes and its relationship to asplenia and phosphatidylserine exposing red blood cells in hemoglobin E/Î²-thalassemia patients. American Journal of Hematology, 2011, 86, 89-92.	2.0	15
137	C-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYC. American Journal of Hematology, 2011, 86, 75-78.	2.0	28
138	Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. American Journal of Hematology, 2011, 86, 102-103.	2.0	46
139	International working group for myelofibrosis research and treatment response assessment and longâ€term followâ€up of 50 myelofibrosis patients treated with thalidomideâ€prednisone based regimens. American Journal of Hematology, 2011, 86, 96-98.	2.0	41
140	Quality of life in thalassemia: A comparison of SFâ€36 results from the thalassemia longitudinal cohort to reported literature and the US norms. American Journal of Hematology, 2011, 86, 92-95.	2.0	63
141	Methotrexateâ€induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. American Journal of Hematology, 2011, 86, 98-101.	2.0	30
142	Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease. American Journal of Hematology, 2011, 86, 104-106.	2.0	18
143	Hepcidin in anemia of chronic heart failure. American Journal of Hematology, 2011, 86, 107-109.	2.0	29
145	Identification of genomic aberrations associated with disease transformation by means of highâ€resolution SNP array analysis in patients with myeloproliferative neoplasm. American Journal of Hematology, 2011, 86, 974-979.	2.0	37
146	Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2011, 86, 1017-1026.	2.0	45
147	Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement. Cancer, 2011, 117, 4869-4877.	2.0	50

#	Article	IF	Citations
148	What are RBC-transfusion-dependence and -independence?. Leukemia Research, 2011, 35, 8-11.	0.4	84
149	Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. Leukemia Research, 2011, 35, 998-1000.	0.4	2
150	Transplantation for myelofibrosis: Time for a randomized trial. Leukemia Research, 2011, 35, 987-988.	0.4	3
151	Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy, 2011, 12, 1597-1611.	0.9	25
152	Management of myelofibrosis â€“ where next?. Expert Opinion on Pharmacotherapy, 2011, 12, 1453-1455.	0.9	2
153	Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplantation, 2011, 46, 557-561.	1.3	19
154	Update on JAK2 inhibitors in myeloproliferative neoplasm. Therapeutic Advances in Hematology, 2011, 2, 61-71.	1.1	3
155	Current Treatment Concepts of Philadelphia-Negative MPN. Current Cancer Drug Targets, 2011, 11, 44-55.	0.8	8
156	Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent. Blood Cancer Journal, 2011, 1, e20-e20.	2.8	7
157	How I treat splenomegaly in myelofibrosis. Blood Cancer Journal, 2011, 1, e37-e37.	2.8	23
158	Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells. Clinical Cancer Research, 2011, 17, 7347-7358.	3.2	90
159	Essential thrombocythemia and primary myelofibrosis. , 2011, , 347-359.		0
160	JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data. Clinical Investigation, 2011, 1, 1681-1693.	0.0	2
161	Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology, 2011, 29, 789-796.	0.8	369
162	Management of Myelofibrosis. Hematology American Society of Hematology Education Program, 2011, 2011, 222-230.	0.9	48
163	Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica, 2011, 96, 1462-1469.	1.7	83
164	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Therapeutic Advances in Hematology, 2012, 3, 341-354.	1.1	50
165	Janus Activated Kinase inhibition in Myelofibrosis. Indian Journal of Cancer, 2012, 49, 260.	0.2	0

#	Article	IF	Citations
166	Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study. Journal of Clinical Oncology, 2012, 30, 2995-3001.	0.8	182
167	Improving Survival Trends in Primary Myelofibrosis: An International Study. Journal of Clinical Oncology, 2012, 30, 2981-2987.	0.8	105
168	New generation small-molecule inhibitors in myeloproliferative neoplasms. Current Opinion in Hematology, 2012, 19, 117-123.	1.2	25
169	Myeloproliferative disorders in older people. Reviews in Clinical Gerontology, 2012, 22, 108-118.	0.5	3
170	U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis. Clinical Cancer Research, 2012, 18, 3212-3217.	3.2	118
171	The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Modern Pathology, 2012, 25, 1193-1202.	2.9	99
172	Emerging targeted therapies in myelofibrosis. Expert Review of Hematology, 2012, 5, 313-324.	1.0	4
173	Emerging drugs for myelofibrosis. Expert Opinion on Emerging Drugs, 2012, 17, 555-570.	1.0	4
174	Very poor outcome of leukemic transformation in myelofibrosis: a single center experience with 13 patients. Leukemia and Lymphoma, 2012, 53, 1236-1238.	0.6	2
175	The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplantation, 2012, 47, 380-386.	1.3	58
176	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 2012, 120, 1202-1209.	0.6	205
177	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. Future Oncology, 2012, 8, 575-593.	1.1	4
178	How to manage the transplant question in myelofibrosis. Blood Cancer Journal, 2012, 2, e59-e59.	2.8	16
179	JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opinion on Investigational Drugs, 2012, 21, 1755-1774.	1.9	16
180	Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Leukemia Supplements, 2012, 1, S2-S7.	0.1	3
181	Management of myelofibrosis: a survey of current practice in the United Kingdom. Journal of Clinical Pathology, 2012, 65, 1124-1127.	1.0	2
182	Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature. Case Reports in Hematology, 2012, 2012, 1-6.	0.3	0
183	Current and Emerging Therapies in Primary Myelofibrosis. Cardiovascular & Hematological Disorders Drug Targets, 2012, 12, 6-20.	0.2	1

#	Article	IF	Citations
185	Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib. Current Medicinal Chemistry, 2012, 19, 4399-4413.	1.2	82
186	Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable. Current Cancer Therapy Reviews, 2012, 8, 14-29.	0.2	2
187	Advances in the Management of Myelofibrosis. Cancer Control, 2012, 19, 4-15.	0.7	11
188	Poor Outcome of Myeloablative Conditioned Allogeneic Bone Marrow Transplantation for Myelofibrosis. Internal Medicine, 2012, 51, 1183-1186.	0.3	0
191	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood, 2012, 119, 2657-2664.	0.6	133
192	Unique features of primary myelofibrosis in Chinese. Blood, 2012, 119, 2469-2473.	0.6	37
193	Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood, 2012, 120, 1367-1379.	0.6	95
194	Ruxolitinib for myelofibrosis. Clinical Investigation, 2012, 2, 1023-1031.	0.0	0
195	Splenic Irradiation as a Component of a Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Myelofibrosis with Massive Splenomegaly. Tohoku Journal of Experimental Medicine, 2012, 228, 295-299.	0.5	16
196	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine, 2012, 366, 799-807.	13.9	1,738
197	JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. New England Journal of Medicine, 2012, 366, 787-798.	13.9	1,543
198	Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leukemia Research, 2012, 36, 1124-1127.	0.4	65
200	One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience. Mayo Clinic Proceedings, 2012, 87, 25-33.	1.4	181
201	WspÃ³Å‚czesne leczenie pierwotnej mielofibrozy. Acta Haematologica Polonica, 2012, 43, 107-112.	0.1	0
202	How I treat polycythemia vera. Blood, 2012, 120, 275-284.	0.6	74
203	JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood, 2012, 119, 2721-2730.	0.6	151
204	Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Review of Hematology, 2012, 5, 631-641.	1.0	3
205	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. , 2012, , 187-199.		0

#	Article	IF	Citations
206	Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis. Clinical Cancer Research, 2012, 18, 3008-3014.	3.2	177
207	Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood, 2012, 120, 3541-3554.	0.6	44
208	Myeloproliferative Neoplasms. Disease-a-Month, 2012, 58, 177-194.	0.4	7
209	A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation. Blood, 2012, 120, 3112-3117.	0.6	33
210	Myelofibrosis 2012: itâ€™s complicated. Therapeutic Advances in Hematology, 2012, 3, 131-146.	1.1	4
211	How to manage polycythemia vera. Leukemia, 2012, 26, 870-874.	3.3	9
212	Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica, 2012, 97, 1574-1581.	1.7	59
213	Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. Expert Opinion on Pharmacotherapy, 2012, 13, 2397-2407.	0.9	36
214	Immunomodulatory agents in myelofibrosis. Expert Opinion on Investigational Drugs, 2012, 21, 1141-1154.	1.9	14
215	Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis. PLoS ONE, 2012, 7, e35631.	1.1	85
216	Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells, Molecules, and Diseases, 2012, 49, 170-176.	0.6	43
217	Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Reviews, 2012, 26, 205-211.	2.8	56
218	SÃndromes mieloproliferativos. Medicine, 2012, 11, 1289-1297.	0.0	1
219	Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture. Leukemia Research, 2012, 36, 1481-1489.	0.4	17
220	MPN blast phase: Clinical challenge and assessing response. Leukemia Research, 2012, 36, 1496-1497.	0.4	9
222	The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Medical Oncology, 2012, 29, 2379-2384.	1.2	10
224	New pieces of a puzzle: The current biological picture of MPN. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 415-422.	3.3	6
225	Clinical Predictors of Outcome in MPN. Hematology/Oncology Clinics of North America, 2012, 26, 1101-1116.	0.9	5

#	Article	IF	Citations
226	GR SNP helps transform myelofibrosis. Blood, 2012, 120, 2934-2935.	0.6	2
227	Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms. Molecular Diagnosis and Therapy, 2012, 16, 269-283.	1.6	14
228	The spectrum of JAK2-positive myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2012, 2012, 561-566.	0.9	34
229	CME Instructions. Cancer Control, 2012, 19, 1-2.	0.7	0
230	Janus kinase inhibitors: jackpot or potluck?. Oncology Reviews, 2012, 6, 13.	0.8	0
231	Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia, 2012, 26, 1439-1441.	3.3	45
232	How to manage children and young adults with myeloproliferative neoplasms. Leukemia, 2012, 26, 1452-1457.	3.3	34
234	Risk models predicting survival after reducedâ€intensity transplantation for myelofibrosis. British Journal of Haematology, 2012, 157, 75-85.	1.2	88
235	Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012. British Journal of Haematology, 2012, 157, 413-425.	1.2	49
236	<scp>J</scp>anus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. British Journal of Haematology, 2012, 157, 426-437.	1.2	19
237	Guideline for the diagnosis and management of myelofibrosis. British Journal of Haematology, 2012, 158, 453-471.	1.2	89
238	Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer, 2012, 118, 870-877.	2.0	10
239	Clinical, histopathologic, and genetic features of pediatric primary myelofibrosisâ€"An entity different from adults. American Journal of Hematology, 2012, 87, 461-464.	2.0	42
240	Prognostication in Primary Myelofibrosis. Current Hematologic Malignancy Reports, 2012, 7, 43-49.	1.2	19
241	Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice. Current Hematologic Malignancy Reports, 2012, 7, 50-56.	1.2	19
242	Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients. Medical Oncology, 2013, 30, 555.	1.2	1
243	Struggling with myelofibrosis-associated anemia. Leukemia Research, 2013, 37, 1429-1431.	0.4	8
244	Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Review of Hematology, 2013, 6, 511-523.	1.0	31

#	Article	IF	Citations
245	The New Landscape of Therapy for Myelofibrosis. Current Hematologic Malignancy Reports, 2013, 8, 325-332.	1.2	13
246	Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 841-852.	1.7	16
247	Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 2013, 31, 1285-1292.	0.8	171
248	Differential diagnosis of myelofibrosis based on <scp>WHO</scp> 2008 criteria: Acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis. International Journal of Laboratory Hematology, 2013, 35, 629-636.	0.7	16
249	Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing. Journal of Hematology and Oncology, 2013, 6, 68.	6.9	14
250	Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy, 2013, 14, 873-884.	0.9	12
251	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	0.6	286
252	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 2013, 122, 4047-4053.	0.6	383
253	Primary myelofibrosis: 2013 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2013, 88, 141-150.	2.0	107
254	Ruxolitinib: A New Treatment Option for Myelofibrosis. Pharmacotherapy, 2013, 33, 84-92.	1.2	24
255	Ruxolitinib for Myelofibrosisâ€“An Update of Its Clinical Effects. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 638-645.	0.2	30
256	Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leukemia Research, 2013, 37, 911-916.	0.4	32
257	Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leukemia Research, 2013, 37, 1509-1515.	0.4	35
258	Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leukemia Research, 2013, 37, 552-555.	0.4	9
259	Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leukemia Research, 2013, 37, 1440-1444.	0.4	25
260	Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance. Clinical Cancer Research, 2013, 19, 1933-1940.	3.2	246
261	Investigational Janus kinase inhibitors. Expert Opinion on Investigational Drugs, 2013, 22, 687-699.	1.9	44
262	Diagnosis and Treatment of Essential Thrombocythemia and Primary Myelofibrosis. , 2013, , 155-168.		0

#	Article	IF	Citations
263	Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leukemia and Lymphoma, 2013, 54, 2537-2539.	0.6	18
264	Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis. Wiener Klinische Wochenschrift, 2013, 125, 196-199.	1.0	5
265	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placeboâ€controlled, Phase <scp>III</scp> study in patients with myelofibrosis. British Journal of Haematology, 2013, 161, 508-516.	1.2	83
266	Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia, 2013, 27, 1322-1327.	3.3	212
267	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	3.3	653
268	Phase <scp>II</scp> trial of panobinostat, an oral panâ€deacetylase inhibitor in patients with primary myelofibrosis, postâ€“essential thrombocythaemia, and postâ€“polycythaemia vera myelofibrosis. British Journal of Haematology, 2013, 162, 326-335.	1.2	61
269	Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 315-318.e2.	0.2	23
270	Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica, 2013, 98, 1872-1876.	1.7	74
271	Update on the treatment of Ph-negative myeloproliferative neoplasms. International Journal of Hematologic Oncology, 2013, 2, 251-262.	0.7	1
272	Advances in myelofibrosis: a clinical case approach. Haematologica, 2013, 98, 1499-1509.	1.7	15
273	Loss of Transfusion Dependency Following Deferasirox Treatment of Iron Overload in a Woman with Myelofibrosis and Spherocytosis - a Case Report. Onkologie, 2013, 36, 205-208.	1.1	11
274	Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease. Modern Pathology, 2013, 26, 204-212.	2.9	70
275	Treatment options for myelofibrosis and myeloproliferative neoplasia. International Journal of Hematologic Oncology, 2013, 2, 487-495.	0.7	1
277	The evolving treatment paradigm in myelofibrosis. Leukemia and Lymphoma, 2013, 54, 242-251.	0.6	20
278	Ruxolitinib: A New Treatment for Myelofibrosis. Clinical Journal of Oncology Nursing, 2013, 17, 312-318.	0.3	5
279	Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis. Postgraduate Medicine, 2013, 125, 128-135.	0.9	45
280	If at First You Don't Succeed: Stem-Cell Transplantation for Acute Myeloid Leukemia After First Relapse. Journal of Clinical Oncology, 2013, 31, 1259-1261.	0.8	1
281	Idiopathic Myelofibrosis in Children. Journal of Pediatric Hematology/Oncology, 2013, 35, 559-565.	0.3	10

#	Article	IF	Citations
282	Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. Journal of Hematology and Oncology, 2013, 6, 81.	6.9	89
283	Efficacy and safety of pegylatedâ€interferon Î±â€2a in myelofibrosis: a study by the <scp>FIM</scp> and <scp>GEM</scp> French cooperative groups. British Journal of Haematology, 2013, 162, 783-791.	1.2	67
284	The <scp>ERCC2 G</scp>ln/<scp>G</scp>ln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. British Journal of Haematology, 2013, 162, 424-427.	1.2	4
285	Mayor Erythropoietic Response after Deferasirox Treatment in a Transfusion-Dependent Anemic Patient with Primary Myelofibrosis. Case Reports in Hematology, 2013, 2013, 1-4.	0.3	6
286	Bilateral Pleural Effusion in a Patient with an Extensive Extramedullary Hematopoietic Mass. Case Reports in Hematology, 2013, 2013, 1-4.	0.3	4
287	Symptom burden and splenomegaly in patients with myelofibrosis in the U nited S tates: a retrospective medical record review. Cancer Medicine, 2013, 2, 889-898.	1.3	30
288	Healthâ€related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 2013, 162, 229-239.	1.2	75
289	Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis. Expert Opinion on Orphan Drugs, 2013, 1, 539-547.	0.5	0
290	Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mateâ€pair sequencing. American Journal of Hematology, 2013, 88, 741-746.	2.0	10
291	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 2013, 27, 1874-1881.	3.3	540
292	JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica, 2013, 98, 722-728.	1.7	66
293	Diagnosis and treatment of myelofibrosis: a personal perspective. Clinical Practice (London, England), 2013, 10, 439-453.	0.1	0
294	A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood, 2013, 121, 4832-4837.	0.6	72
295	Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica, 2013, 98, 1865-1871.	1.7	143
296	Stem Cell Transplantation in Primary Myelofibrosis of Childhood. Journal of Pediatric Hematology/Oncology, 2013, 35, e120-e122.	0.3	10
298	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. OncoTargets and Therapy, 2013, 7, 13.	1.0	46
299	Ruxolitinib for myelofibrosis. Experimental and Therapeutic Medicine, 2013, 5, 927-931.	0.8	1
300	Treatment and management of myelofibrosis in the era of JAK inhibitors. Biologics: Targets and Therapy, 2013, 7, 189.	3.0	12

#	Article	IF	Citations
301	Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib. Clinical Medicine Insights Therapeutics, 2013, 5, CMT.S9566.	0.4	0
302	Ruxolitinib as an emerging treatment in myelofibrosis. Blood and Lymphatic Cancer: Targets and Therapy, 2013, , 11.	1.2	0
303	Coexistence of primary myelofibrosis and chronic lymphocytic leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 2014, , 101.	1.2	0
304	Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. International Journal of General Medicine, 2014, 7, 89.	0.8	53
305	Profile of pacritinib and its potential in the treatment of hematologic disorders. Journal of Blood Medicine, 2014, 5, 143.	0.7	21
307	Advances in the Inhibitors of Janus Kinase. , 2014, 4, .		2
308	Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Post-Treatment Megakaryocytic Hyperplasia with JAK-2 Mutation. American Journal of Clinical Pathology, 2014, 142, A103-A103.	0.4	0
309	Givinostat for the treatment of polycythemia vera. Expert Opinion on Orphan Drugs, 2014, 2, 841-850.	0.5	1
310	Orphan drugs for myelofibrosis. Expert Opinion on Orphan Drugs, 2014, 2, 391-405.	0.5	2
311	Ruxolitinib for the treatment of primary myelofibrosis. American Journal of Health-System Pharmacy, 2014, 71, 453-462.	0.5	13
312	Therapy for myeloproliferative neoplasms: when, which agent, and how?. Hematology American Society of Hematology Education Program, 2014, 2014, 277-286.	0.9	25
313	Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT. Bone Marrow Transplantation, 2014, 49, 355-360.	1.3	33
314	JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia, 2014, 28, 1736-1738.	3.3	90
315	Anti-transforming growth factor-Î² therapy in patients with myelofibrosis. Leukemia and Lymphoma, 2014, 55, 450-452.	0.6	45
316	Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval. Leukemia and Lymphoma, 2014, 55, 195-197.	0.6	22
317	Optimizing the Management of Patients With Myelofibrosis. Clinical Journal of Oncology Nursing, 2014, 18, 330-337.	0.3	2
318	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	0.6	340
319	Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. Journal of Medical Economics, 2014, 17, 435-441.	1.0	8

#	Article	IF	Citations
320	CALR mutation screening in pediatric primary myelofibrosis. Pediatric Blood and Cancer, 2014, 61, 2256-2262.	0.8	21
321	Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative Disease. Hematology/Oncology Clinics of North America, 2014, 28, 1023-1035.	0.9	6
322	Allogeneic Stem Cell Transplant vs. Janus Kinase Inhibition in the Treatment of Primary Myelofibrosis or Myelofibrosis After Essential Thrombocythemia or Polycythemia Vera. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S36-S41.	0.2	6
323	Comorbidities predict worse prognosis in patients with primary myelofibrosis. Cancer, 2014, 120, 2996-3002.	2.0	31
324	Ruxolitinib: Long-Term Management of Patients with Myelofibrosis and Future Directions in the Treatment of Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2014, 9, 350-359.	1.2	8
325	Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Current Opinion in Hematology, 2014, 21, 65-71.	1.2	33
326	Ruxolitinib. Recent Results in Cancer Research, 2014, 201, 249-257.	1.8	17
327	Allogeneic transplantation for myelofibrosis. Current Opinion in Hematology, 2014, 21, 114-122.	1.2	7
328	High spontaneous granulocyte/macrophage-colony formation in patients with myelofibrosis. Leukemia Research, 2014, 38, 116-120.	0.4	1
329	Are we altering the natural history of primary myelofibrosis?. Leukemia Research, 2014, 38, 1004-1012.	0.4	26
330	Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. Annals of Hematology, 2014, 93, 797-802.	0.8	10
331	Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia, 2014, 28, 1568-1570.	3.3	142
332	Thrombosis in Myeloproliferative Neoplasms. Seminars in Thrombosis and Hemostasis, 2014, 40, 348-358.	1.5	84
333	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	0.6	115
334	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia, 2014, 28, 1494-1500.	3.3	248
335	Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis. Medical Oncology, 2014, 31, 869.	1.2	34
336	Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Annals of Hematology, 2014, 93, 57-64.	0.8	16
337	Small Molecules in Oncology. Recent Results in Cancer Research, 2014, , .	1.8	4

#	Article	IF	Citations
338	Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia, 2014, 28, 958-961.	3.3	59
340	Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia, 2014, 28, 1486-1493.	3.3	50
342	Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein. Leukemia, 2014, 28, 961-964.	3.3	10
343	Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the <scp>E</scp>uropean <scp>U</scp>nion. European Journal of Haematology, 2014, 92, 289-297.	1.1	190
344	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leukemia Research, 2014, 38, 1126-1129.	0.4	29
345	Does anything work for anaemia in myelofibrosis?. Best Practice and Research in Clinical Haematology, 2014, 27, 175-185.	0.7	10
346	How many JAK inhibitors in myelofibrosis?. Best Practice and Research in Clinical Haematology, 2014, 27, 187-195.	0.7	5
347	Controversies and dilemmas in allogeneic transplantation for myelofibrosis. Best Practice and Research in Clinical Haematology, 2014, 27, 165-174.	0.7	3
348	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	3.3	263
349	Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter. Best Practice and Research in Clinical Haematology, 2014, 27, 129-140.	0.7	43
350	Leukemic transformation in myeloproliferative neoplasms: Therapy-related or unrelated?. Best Practice and Research in Clinical Haematology, 2014, 27, 141-153.	0.7	40
351	A closer look at pacritinib: a JAK2/FLT3 inhibitor for the treatment of myelofibrosis. Expert Opinion on Orphan Drugs, 2014, 2, 725-733.	0.5	4
352	Prognostication in MF: From CBC to cytogenetics to molecular markers. Best Practice and Research in Clinical Haematology, 2014, 27, 155-164.	0.7	8
353	Primary myelofibrosis: 2014 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2014, 89, 915-925.	2.0	88
354	Assessing disease burden in patients with classic MPNs. Best Practice and Research in Clinical Haematology, 2014, 27, 107-119.	0.7	7
355	Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. Journal of Hematology and Oncology, 2014, 7, 18.	6.9	30
356	Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplantation, 2014, 49, 179-184.	1.3	98
357	Efficacy of ruxolitinib for myelofibrosis. Expert Opinion on Pharmacotherapy, 2014, 15, 1465-1473.	0.9	10

#	Article	IF	Citations
358	Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis. Leukemia Research, 2014, 38, 1207-1211.	0.4	6
359	Quality of Life in MPN Comes of Age as a Therapeutic Target. Current Hematologic Malignancy Reports, 2014, 9, 324-330.	1.2	15
360	The future of JAK inhibition in myelofibrosis and beyond. Blood Reviews, 2014, 28, 189-196.	2.8	25
361	Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert Opinion on Pharmacotherapy, 2014, 15, 1265-1276.	0.9	31
362	Conceptos bÃ¡sicos sobre sÃndromes mielo y linfoproliferativos. FMC Formacion Medica Continuada En Atencion Primaria, 2014, 21, 17-25.	0.0	0
363	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2014, 20, 89-97.	2.0	130
364	Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2014, 20, 1274-1281.	2.0	18
365	Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 2014, 20, 812-815.	2.0	46
366	Pierwotna mielofibroza â€“ przeglÄ…d metod leczniczych. Acta Haematologica Polonica, 2014, 45, 143-148.	0.1	1
367	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. Leukemia Research, 2014, 38, 155-160.	0.4	28
368	Myeloproliferative Disorders. Emergency Medicine Clinics of North America, 2014, 32, 597-612.	0.5	10
369	Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples. Experimental Hematology, 2014, 42, 816-825.	0.2	22
370	Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leukemia and Lymphoma, 2014, 55, 121-127.	0.6	49
371	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2014, 99, 916-921.	1.7	62
372	The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica, 2014, 99, e55-e57.	1.7	51
373	Mutational spectrum defines primary and secondary myelofibrosis. Haematologica, 2014, 99, 2-3.	1.7	10
374	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 2014, 99, 292-298.	1.7	38
375	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 2014, 123, 1833-1835.	0.6	95

#	Article	IF	Citations
376	Changing myelofibrosisâ€™s natural course at last. Blood, 2014, 123, 1776-1777.	0.6	5
377	Therapy for myeloproliferative neoplasms: when, which agent, and how?. Blood, 2014, 124, 3529-3537.	0.6	86
378	How I treat myelofibrosis. Blood, 2014, 124, 2635-2642.	0.6	132
379	Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase. Haematologica, 2014, 99, 37-45.	1.7	38
380	Imatinib and ruxolitinib association: first experience in two patients. Haematologica, 2014, 99, e76-e77.	1.7	26
381	Ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adult patients with myelofibrosis. International Journal of Hematologic Oncology, 2014, 3, 335-342.	0.7	1
382	Ruksolitynib w leczeniu nowotworÃ³w mieloproliferacyjnych Ph(-). Acta Haematologica Polonica, 2015, 46, 292-298.	0.1	0
383	Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs). Hematology American Society of Hematology Education Program, 2015, 2015, 649-651.	0.9	1
384	Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis. Hematology American Society of Hematology Education Program, 2015, 2015, 329-339.	0.9	10
385	JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice. Journal of Cellular and Molecular Medicine, 2015, 19, 2564-2574.	1.6	5
387	Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. The Cochrane Library, 2015, 2015, CD010298.	1.5	31
388	Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood, 2015, 125, 2649-2655.	0.6	107
389	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood, 2015, 126, 1551-1554.	0.6	151
393	1. Therapeutic Strategy for Myeloproliferative Neoplasms. The Journal of the Japanese Society of Internal Medicine, 2015, 104, 1918-1923.	0.0	0
394	CD133 marks a stem cell population that drives human primary myelofibrosis. Haematologica, 2015, 100, 768-779.	1.7	13
395	Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 424-434.	2.3	24
398	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. Journal of Translational Medicine, 2015, 13, 294.	1.8	36
399	The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Experimental Hematology and Oncology, 2015, 4, 26.	2.0	36

#	Article	IF	Citations
400	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 2015, 100, 479-488.	1.7	246
401	Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. American Journal of Hematology, 2015, 90, n/a-n/a.	2.0	0
402	Effect of food on the bioavailability and tolerability of the JAK2â€selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers. Clinical Pharmacology in Drug Development, 2015, 4, 315-321.	0.8	30
403	Assessment of Liver and Spleen Stiffness in Patients With Myelofibrosis Using FibroScan and Shear Wave Elastography. Ultrasound Quarterly, 2015, 31, 166-169.	0.3	17
404	Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2â€mutated polycythemia vera. American Journal of Hematology, 2015, 90, 1116-1121.	2.0	14
405	Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development. Mediators of Inflammation, 2015, 2015, 1-9.	1.4	94
406	Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. Mediators of Inflammation, 2015, 2015, 1-16.	1.4	54
407	Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. OncoTargets and Therapy, 2015, 8, 1091.	1.0	17
408	Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. Journal of Blood Medicine, 2015, 6, 157.	0.7	18
409	Guidelines for the management of myeloproliferative neoplasms. Korean Journal of Internal Medicine, 2015, 30, 771-788.	0.7	22
410	Profile of pomalidomide and its potential in the treatment of myelofibrosis. Therapeutics and Clinical Risk Management, 2015, 11, 549.	0.9	6
412	Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib. Advances in Hematology, 2015, 2015, 1-9.	0.6	20
413	Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation ofJAK2V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation. Case Reports in Hematology, 2015, 2015, 1-4.	0.3	1
414	From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 139-145.	1.8	6
415	Current Therapies and Their Indications for the Philadelphia-Negative Myeloproliferative Neoplasms. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e389-e396.	1.8	6
416	Myeloproliferative disorders apart from chronic myeloid leukemias. Hematologie, 2015, 21, 348-356.	0.0	0
417	Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms. Current Opinion in Hematology, 2015, 22, 184-190.	1.2	6
418	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood, 2015, 125, 3347-3350.	0.6	152

#	Article	IF	Citations
420	Clinical potential of pacritinib in the treatment of myelofibrosis. Therapeutic Advances in Hematology, 2015, 6, 186-201.	1.1	13
421	Practical management of myelofibrosis with ruxolitinib. Internal Medicine Journal, 2015, 45, 1221-1230.	0.5	7
422	Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26, v85-v99.	0.6	105
423	Data Resource Profile: The Human Mortality Database (HMD). International Journal of Epidemiology, 2015, 44, 1549-1556.	0.9	103
424	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica, 2015, 100, 1139-1145.	1.7	203
425	Social Media and Myeloproliferative Neoplasms (MPN)â€"Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. Current Hematologic Malignancy Reports, 2015, 10, 413-420.	1.2	22
426	How we manage <scp>JAK</scp> inhibition in allogeneic transplantation for myelofibrosis. European Journal of Haematology, 2015, 94, 115-119.	1.1	14
427	PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis. Leukemia Research, 2015, 39, 236-241.	0.4	10
428	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. Leukemia Research, 2015, 39, 314-317.	0.4	11
429	Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?. Bone Marrow Transplantation, 2015, 50, 628-636.	1.3	13
430	Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis. Drugs, 2015, 75, 297-308.	4.9	60
431	A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis. International Journal of Hematology, 2015, 101, 295-304.	0.7	10
432	Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 696-705.	3.3	16
433	Emerging drugs for the treatment of myelofibrosis. Expert Opinion on Emerging Drugs, 2015, 20, 663-678.	1.0	5
434	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. Journal of Clinical Oncology, 2015, 33, 2288-2295.	0.8	106
435	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2092-2097.	0.6	51
436	Protein kinase CÉ› inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients. Leukemia, 2015, 29, 2192-2201.	3.3	19
437	An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation. Blood Cells, Molecules, and Diseases, 2015, 55, 347-350.	0.6	3

#	Article	IF	Citations
438	Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Annals of Hematology, 2015, 94, 1791-1796.	0.8	57
439	Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2067-2074.	0.6	25
440	Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. Blood Cancer Journal, 2015, 5, e286-e286.	2.8	7
441	Myelofibrosis patients in Belgium: disease characteristics. Acta Clinica Belgica, 2015, 70, 105-111.	0.5	7
442	Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 253-261.	0.2	16
443	Secondary Acute Myeloid Leukemias Arising From Philadelphia Chromosome Negative Myeloproliferative Neoplasms: Pathogenesis, Risk Factors, and Therapeutic Strategies. Current Hematologic Malignancy Reports, 2015, 10, 112-117.	1.2	16
444	Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncology, 2015, 11, 719-733.	1.1	59
445	Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors. Leukemia and Lymphoma, 2015, 56, 1989-1999.	0.6	28
446	Novel Insights into Myelofibrosis Pathophysiology and Treatment. , 2015, , .		0
447	Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 3.	0.1	16
448	Clinical and molecular genetic characterization of myelofibrosis. Current Opinion in Hematology, 2015, 22, 177-183.	1.2	14
449	Response to ruxolitinib in patients with intermediateâ€1â€“, intermediateâ€2â€“, and highâ€risk myelofibrosis: results of the <scp>UK ROBUST</scp> Trial. British Journal of Haematology, 2015, 170, 29-39.	1.2	82
450	What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?. Current Hematologic Malignancy Reports, 2015, 10, 380-387.	1.2	1
451	Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide. Expert Review of Hematology, 2015, 8, 819-835.	1.0	0
452	Anemia of Central Origin. Seminars in Hematology, 2015, 52, 321-338.	1.8	9
453	Pacritinib: a new agent for the management of myelofibrosis?. Expert Opinion on Pharmacotherapy, 2015, 16, 2381-2390.	0.9	8
454	Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 715-727.	0.2	7
455	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology, 2015, 1, 643.	3.4	362

#	Article	IF	Citations
456	Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. Annals of Hematology, 2015, 94, 1797-1806.	0.8	13
457	A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer Journal, 2015, 5, e335-e335.	2.8	75
458	Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis. Current Hematologic Malignancy Reports, 2015, 10, 362-369.	1.2	1
459	Recombinant interferon-Î± in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Modern Pathology, 2015, 28, 1315-1323.	2.9	49
460	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia, 2015, 29, 2126-2133.	3.3	242
461	How We Treat Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S19-S26.	0.2	0
462	Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S34-S42.	0.2	0
463	Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica, 2015, 100, 1058-63.	1.7	46
464	Biologie des syndromes myÃ©loprolifÃ©ratifs : classifications diagnostiques et nouveaux marqueurs molÃ©culaires. Revue Francophone Des Laboratoires, 2015, 2015, 35-45.	0.0	1
465	Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 214-221.e1.	0.2	63
466	Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia, 2015, 29, 20-26.	3.3	40
467	Accurately assessing risk in your myeloproliferative neoplasm patient. , 0, , 37-44.		0
468	Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment. , 0, , 79-85.		0
469	Emerging treatment options for myelofibrosis: focus on pacritinib. OncoTargets and Therapy, 2016, 9, 2655.	1.0	2
470	Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. OncoTargets and Therapy, 2016, 9, 2273.	1.0	5
471	Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e324-e335.	1.8	8
472	Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation. Case Reports in Hematology, 2016, 2016, 1-5.	0.3	3
473	Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. OncoTargets and Therapy, 2016, Volume 9, 4937-4957.	1.0	13

#	Article	IF	Citations
474	Hematopoietic cell transplantation for myelofibrosis: who and when?. , 0, , 86-96.		0
475	Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. British Journal of Haematology, 2016, 175, 37-42.	1.2	9
476	Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. European Journal of Haematology, 2016, 96, 643-649.	1.1	19
477	The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer, 2016, 122, 681-692.	2.0	17
478	Safety and outcome of allogeneic stem cell transplantation in myelofibrosis. European Journal of Haematology, 2016, 96, 222-228.	1.1	2
479	MR Imaging in nonâ€hepatosplenic extramedullary hematopoiesis in primary myelofibrosis. American Journal of Hematology, 2016, 91, 1062-1063.	2.0	1
480	Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches. Expert Review of Hematology, 2016, 9, 851-859.	1.0	3
481	Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review. Medical Principles and Practice, 2016, 25, 501-509.	1.1	9
482	Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis. Internal Medicine, 2016, 55, 1977-1984.	0.3	8
483	The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica, 2016, 101, e482-e484.	1.7	50
484	SÃndromes mieloproliferativos. Medicine, 2016, 12, 1213-1223.	0.0	0
485	Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Reviews, 2016, 30, 349-356.	2.8	16
486	Safety considerations when treating myelofibrosis. Expert Opinion on Drug Safety, 2016, 15, 1185-1192.	1.0	6
487	New drugs for myelofibrosis. Expert Opinion on Orphan Drugs, 2016, 4, 521-529.	0.5	2
488	Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer Journal, 2016, 6, e415-e415.	2.8	14
489	The development, safety and efficacy of pacritinib for the treatment of myelofibrosis. Expert Review of Anticancer Therapy, 2016, 16, 1101-1108.	1.1	8
490	Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood, 2016, 128, 877-880.	0.6	6
491	Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis. International Journal of Hematology, 2016, 104, 476-484.	0.7	12

#	Article	IF	Citations
492	Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis. Haematologica, 2016, 101, e405-e406.	1.7	20
494	Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. Leukemia and Lymphoma, 2016, 57, 2259-2267.	0.6	16
495	The Degree of Anisocytosis Predicts Survival in Patients with Primary Myelofibrosis. Acta Haematologica, 2016, 136, 98-100.	0.7	16
496	Myeloproliferative neoplasms: A decade of discoveries and treatment advances. American Journal of Hematology, 2016, 91, 50-58.	2.0	150
497	Myeloproliferative neoplasms: Morphology and clinical practice. American Journal of Hematology, 2016, 91, 430-433.	2.0	39
498	Ruxolitinib dose management as a key to long-term treatment success. International Journal of Hematology, 2016, 104, 420-429.	0.7	10
499	Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica, 2016, 101, 1065-1073.	1.7	130
500	A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S124-S129.	0.2	21
501	Prognosis of Primary Myelofibrosis in the Genomic Era. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S105-S113.	0.2	12
502	Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential thrombocythemia myelofibrosis in the Chinese population. Frontiers of Medicine, 2016, 10, 437-443.	1.5	2
503	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. Biology of Blood and Marrow Transplantation, 2016, 22, 2180-2186.	2.0	20
504	CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis. Annals of Hematology, 2016, 95, 1965-1969.	0.8	7
505	Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood, 2016, 127, 3410-3423.	0.6	78
506	Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacological Research, 2016, 111, 784-803.	3.1	279
507	Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review. Journal of Oncology Practice, 2016, 12, 611-621.	2.5	17
508	Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Annals of Hematology, 2016, 95, 1391-1398.	0.8	17
509	A unique presentation of pulmonary disease in advanced systemic mastocytosis, proven by the presence of mast cells in bronchoalveolar lavage: a case report. Journal of Medical Case Reports, 2016, 10, 283.	0.4	4
510	Primary myelofibrosis: 2017 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2016, 91, 1262-1271.	2.0	130

#	Article	IF	Citations
511	Myelofibrosis: an update on drug therapy in 2016. Expert Opinion on Pharmacotherapy, 2016, 17, 2375-2389.	0.9	9
512	Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opinion on Investigational Drugs, 2016, 25, 1393-1403.	1.9	25
513	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	2.0	80
514	Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPNâ€associated myelofibrosis. American Journal of Hematology, 2016, 91, 709-713.	2.0	6
515	Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica, 2016, 101, 660-671.	1.7	120
516	Histone deacetylase inhibitors in myeloproliferative neoplasms: current roles and future prospects. Expert Opinion on Orphan Drugs, 2016, 4, 417-427.	0.5	1
517	Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia, 2016, 30, 1701-1707.	3.3	393
518	Continued Role of Splenectomy in the Management of Patients With Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e133-e137.	0.2	10
519	Hematological manifestations of human T lymphotropic virus type 1 infection: a possible association with autoimmune myelofibrosis. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 75-78.	0.7	0
520	Primary myelofibrosis: current therapeutic options. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 257-263.	0.7	8
521	Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians. Annals of Hematology, 2016, 95, 1399-1410.	0.8	6
522	Highly variable mutational profile of <scp>ASXL</scp>1 in myelofibrosis. European Journal of Haematology, 2016, 97, 331-335.	1.1	6
523	Myeloproliferative neoplasms: Current molecular biology and genetics. Critical Reviews in Oncology/Hematology, 2016, 98, 375-389.	2.0	43
524	New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms. Current Opinion in Hematology, 2016, 23, 137-143.	1.2	23
525	Ruxolitinib is an effective treatment for <scp>CALR</scp>â€positive patients with myelofibrosis. British Journal of Haematology, 2016, 173, 938-940.	1.2	36
526	Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia. American Journal of Hematology, 2016, 91, 123-130.	2.0	6
527	Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemotherapy and Pharmacology, 2016, 77, 1125-1142.	1.1	36
528	Disordered haematopoiesis and athero-thrombosis. European Heart Journal, 2016, 37, 1113-1121.	1.0	86

#	Article	IF	Citations
529	Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. Leukemia, 2016, 30, 1413-1415.	3.3	7
530	Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis. Hematology, 2016, 21, 10-18.	0.7	3
531	Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan. Hematology, 2016, 21, 3-9.	0.7	8
532	Alleviating anemia and thrombocytopenia in myelofibrosis patients. Expert Review of Hematology, 2016, 9, 489-496.	1.0	13
533	Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leukemia and Lymphoma, 2016, 57, 2464-2467.	0.6	28
534	New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. Clinical Cancer Research, 2016, 22, 1037-1047.	3.2	13
535	Pharmacoeconomics of ruxolitinib therapy in patients with myelofibrosis. Journal of Medical Economics, 2016, 19, 424-431.	1.0	4
536	Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leukemia and Lymphoma, 2016, 57, 1054-1059.	0.6	18
537	Long-term results of prednisone treatment for the anemia of myelofibrosis. Leukemia and Lymphoma, 2016, 57, 120-124.	0.6	16
538	Ruxolitinib â€“ better prognostic impact in low-intermediate 1 risk score: evaluation of the â€˜rete ematologica pugliese â€™ (REP) in primary and secondary myelofibrosis. Leukemia and Lymphoma, 2017, 58, 138-144.	0.6	6
539	Managing patients with myelofibrosis and low platelet counts. Annals of Hematology, 2017, 96, 537-548.	0.8	12
540	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of Hematology and Oncology, 2017, 10, 55.	6.9	302
541	Heat shock protein 27 (HSP27/HSPB1) expression is increased in patients with primary and secondary myelofibrosis and may be affecting their survival. Leukemia and Lymphoma, 2017, 58, 2497-2500.	0.6	8
542	JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms. Molecular and Cellular Endocrinology, 2017, 451, 71-79.	1.6	31
543	Management of myelofibrosis: JAK inhibition and beyond. Expert Review of Hematology, 2017, 10, 459-477.	1.0	11
544	Allogeneic Stem Cell Transplantation in Myelofibrosis. Biology of Blood and Marrow Transplantation, 2017, 23, 1429-1436.	2.0	29
545	JAK2 inhibitors for myeloproliferative neoplasms: what is next?. Blood, 2017, 130, 115-125.	0.6	86
546	Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 479-487.	0.2	21

#	Article	IF	Citations
547	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica, 2017, 102, 94-102.	1.7	80
548	Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. Expert Review of Hematology, 2017, 10, 627-636.	1.0	0
549	Sclt1 deficiency causes cystic kidney by activating ERK and STAT3 signaling. Human Molecular Genetics, 2017, 26, 2949-2960.	1.4	28
550	Investigational Janus kinase inhibitors in development for myelofibrosis. Expert Opinion on Investigational Drugs, 2017, 26, 723-734.	1.9	10
551	Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. Expert Review of Hematology, 2017, 10, 617-625.	1.0	29
552	Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. Leukemia Research, 2017, 60, 18-23.	0.4	27
553	Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leukemia Research, 2017, 59, 26-31.	0.4	14
554	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2726-2731.	3.3	242
555	Myeloproliferative Neoplasms. New England Journal of Medicine, 2017, 376, 2168-2181.	13.9	274
556	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and <scp>JAK</scp> inhibitors era?. European Journal of Haematology, 2017, 99, 60-69.	1.1	5
557	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	0.6	137
559	Predictive factors for anemia response to erythropoiesisâ€stimulating agents in myelofibrosis. European Journal of Haematology, 2017, 98, 407-414.	1.1	23
560	Does ruxolitinib prolong the survival of patients with myelofibrosis?. Blood, 2017, 129, 832-837.	0.6	81
561	Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004â€“2013. Annals of Hematology, 2017, 96, 373-381.	0.8	29
562	Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood, 2017, 129, 680-692.	0.6	199
563	Emerging treatments for classical myeloproliferative neoplasms. Blood, 2017, 129, 693-703.	0.6	84
564	From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. Haematologica, 2017, 102, 18-29.	1.7	16
565	An accurate, simple prognostic model consisting of age, JAK2 , CALR , and MPL mutation status for patients with primary myelofibrosis. Haematologica, 2017, 102, 79-84.	1.7	30

#	Article	IF	Citations
566	Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wiener Klinische Wochenschrift, 2017, 129, 293-302.	1.0	6
567	Treatment of Myelofibrosis: Old and New Strategies. Clinical Medicine Insights Blood Disorders, 2017, 10, 1179545X1769523.	0.3	21
568	Myeloproliferative Disorders. Hematology/Oncology Clinics of North America, 2017, 31, 1029-1044.	0.9	12
569	JSH guideline for tumors of hematopoietic and lymphoid tissuesâ€"lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). International Journal of Hematology, 2017, 106, 591-611.	0.7	19
570	Management of Post ET/PV MF: Different from Primary MF. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S24-S26.	0.2	0
571	Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. Current Hematologic Malignancy Reports, 2017, 12, 397-405.	1.2	9
572	Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2851-2852.	3.3	30
573	Progression of primary myelofibrosis to polycythemia vera. Medicine (United States), 2017, 96, e7464.	0.4	1
574	The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Annals of Hematology, 2017, 96, 1595-1604.	0.8	38
575	Immunotherapy based approaches in myelofibrosis. Expert Review of Hematology, 2017, 10, 903-914.	1.0	12
576	Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clinic Proceedings, 2017, 92, 1283-1290.	1.4	53
577	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Annals of Hematology, 2017, 96, 1653-1665.	0.8	92
578	Myeloproliferative neoplasms: from origins to outcomes. Blood, 2017, 130, 2475-2483.	0.6	107
579	Leukemic Transformation in Myeloproliferative Neoplasms. Mayo Clinic Proceedings, 2017, 92, 1118-1128.	1.4	83
580	Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 774-781.	0.2	6
581	Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-Î²1 and Cxcl12 pathways. Blood, 2017, 130, 920-932.	0.6	19
582	Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. International Journal of Hematology, 2017, 105, 309-317.	0.7	13
583	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia, 2017, 31, 882-888.	3.3	40

#	Article	IF	Citations
584	Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. International Journal of Hematology, 2017, 105, 59-69.	0.7	13
585	A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia, 2017, 31, 896-902.	3.3	54
586	Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. Future Oncology, 2017, 13, 395-407.	1.1	10
587	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma, 2017, 58, 866-871.	0.6	4
588	New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment. Hematological Oncology, 2017, 35, 145-150.	0.8	2
589	Primary myelofibrosis and its targeted therapy. Annals of Hematology, 2017, 96, 531-535.	0.8	6
590	A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence. Pharmacoeconomics, 2017, 35, 203-213.	1.7	6
591	Peripheral and bone marrow CD34⁺ cell levels on chronic myeloproliferative disease. Hematology, 2017, 22, 74-80.	0.7	3
592	Pharmacologic management of myelofibrosis. Journal of Oncology Pharmacy Practice, 2017, 23, 591-601.	0.5	2
594	A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia, 2017, 31, 393-402.	3.3	40
595	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. American Journal of Hematology, 2017, 92, 37-41.	2.0	62
596	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews, 2017, 31, 17-29.	2.8	98
597	Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. Blood Cancer Journal, 2017, 7, 657.	2.8	13
599	Allogeneic hematopoietic cell transplants for BCR/ABL negative myeloproliferative neoplasms. , 0, , 351-360.		0
600	Myeloproliferative neoplasms: from origins to outcomes. Hematology American Society of Hematology Education Program, 2017, 2017, 470-479.	0.9	29
601	Molecular Testing in Myeloproliferative Neoplasms. , 2017, , 435-447.		0
602	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. Journal of Hematology and Oncology, 2017, 10, 156.	6.9	210
603	Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation. Internal Medicine, 2017, 56, 2481-2485.	0.3	7

#	Article	IF	Citations
604	Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure. Hematology Reports, 2017, 9, 7091.	0.3	0
605	Monosomal karyotype in myeloid neoplasias: a literature review. OncoTargets and Therapy, 2017, Volume 10, 2163-2171.	1.0	13
606	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitorâ€“NaÃ¯ve Patients With Myelofibrosis. Journal of Clinical Oncology, 2017, 35, 3844-3850.	0.8	243
607	Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. Annals of Hematology, 2018, 97, 745-754.	0.8	11
608	Emerging drugs for the treatment of Myelofibrosis. Expert Opinion on Emerging Drugs, 2018, 23, 37-49.	1.0	11
609	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. JAMA Oncology, 2018, 4, 652.	3.4	261
610	Allogeneic transplantation for myelofibrosis with adverse risk karyotype: Attack on the clones?. American Journal of Hematology, 2018, 93, 603-604.	2.0	1
611	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	3.3	415
612	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 2018, 32, 1631-1642.	3.3	213
613	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematological Oncology, 2018, 36, 561-569.	0.8	46
614	The role of JAK2 inhibitors in MPNs 7 years after approval. Blood, 2018, 131, 2426-2435.	0.6	40
615	Prognostic implications of low transferrin saturation in patients with primary myelofibrosis. Leukemia Research, 2018, 66, 89-95.	0.4	6
616	Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia, 2018, 32, 1254-1258.	3.3	42
617	Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis. Wiener Klinische Wochenschrift, 2018, 130, 126-133.	1.0	22
618	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms. Annals of Internal Medicine, 2018, 168, 317.	2.0	177
619	Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer Journal, 2018, 8, 9.	2.8	30
620	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia, 2018, 32, 1189-1199.	3.3	102
621	Prognostic risk models for transplant decision-making in myelofibrosis. Annals of Hematology, 2018, 97, 813-820.	0.8	7

#	Article	IF	Citations
622	Driver mutations in primary myelofibrosis and their implications. Current Opinion in Hematology, 2018, 25, 129-135.	1.2	15
623	Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. Current Hematologic Malignancy Reports, 2018, 13, 173-182.	1.2	19
624	Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. Journal of Hematology and Oncology, 2018, 11, 42.	6.9	63
625	Combination Therapy with Ruxolitinib and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a Patient with Myelofibrosis. Acta Haematologica, 2018, 139, 164-165.	0.7	4
626	Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e201-e210.	0.2	0
627	Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis. Annals of Hematology, 2018, 97, 1293-1294.	0.8	0
628	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. British Journal of Haematology, 2018, 181, 397-400.	1.2	34
629	Efficacy and safety of ruxolitinib in intermediateâ€1 IPSS risk myelofibrosis patients: Results from an independent study. Hematological Oncology, 2018, 36, 285-290.	0.8	29
630	Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. Haematologica, 2018, 103, e5-e9.	1.7	18
631	Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis. Leukemia, 2018, 32, 837-839.	3.3	29
632	An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. Future Oncology, 2018, 14, 137-150.	1.1	11
633	Recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology, 2018, 23, 194-200.	0.7	2
634	Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. International Journal of Hematology, 2018, 107, 92-97.	0.7	5
635	Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis. International Journal of Hematology, 2018, 107, 166-172.	0.7	8
636	Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia, 2018, 32, 553-555.	3.3	23
637	High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis. Hematology, 2018, 23, 201-207.	0.7	6
638	Screening for <scp>ASXL</scp>1 and <scp>SRSF</scp>2 mutations is imperative for treatment decisionâ€making in otherwise low or intermediateâ€1 risk patients with myelofibrosis. British Journal of Haematology, 2018, 183, 678-681.	1.2	19
639	Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Annals of Hematology, 2018, 97, 435-441.	0.8	95

#	Article	IF	Citations
640	Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. Current Medical Research and Opinion, 2018, 34, 531-537.	0.9	5
641	Polycythemia vera and essential thrombocythemia: algorithmic approach. Current Opinion in Hematology, 2018, 25, 112-119.	1.2	12
642	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. American Journal of Hematology, 2018, 93, 277-285.	2.0	54
643	Recent advances in the diagnosis and management of primary myelofibrosis. Korean Journal of Internal Medicine, 2018, 33, 679-690.	0.7	17
644	Primary Myelofibrosis with MPL S505N Mutation: The First Case Reported in Korea. Laboratory Medicine Online, 2018, 8, 167.	0.0	0
645	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	0.8	373
646	Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation. Medicine (United States), 2018, 97, e11331.	0.4	3
647	Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 104.	2.8	32
648	Megakaryocyte contribution to bone marrow fibrosis: many arrows in the quiver. Mediterranean Journal of Hematology and Infectious Diseases, 2018, 10, e2018068.	0.5	40
649	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	2.8	13
650	Mutational landscape of myelodysplastic/myeloproliferative neoplasmâ€“unclassifiable. Blood, 2018, 132, 2100-2103.	0.6	40
651	Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance. Oncology Reviews, 2018, 12, 373.	0.8	4
652	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leukemia Research, 2018, 74, 86-88.	0.4	23
653	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	13.9	442
654	Novel treatments to tackle myelofibrosis. Expert Review of Hematology, 2018, 11, 889-902.	1.0	1
656	JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology American Society of Hematology Education Program, 2018, 2018, 110-117.	0.9	7
658	Management of Myelofibrosis-Related Cytopenias. Current Hematologic Malignancy Reports, 2018, 13, 164-172.	1.2	20
659	Chronic myeloproliferative neoplasms in the elderly. European Journal of Internal Medicine, 2018, 58, 33-42.	1.0	2

#	Article	IF	Citations
660	Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer Journal, 2018, 8, 64.	2.8	47
661	Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e463-e468.	0.2	25
662	Myelofibrosis Treatment Algorithm 2018. Blood Cancer Journal, 2018, 8, 72.	2.8	31
663	Clonal evolution of myelofibrosis treated with hematopoietic transplantation, using RUXOLITINIB for chronic GvHD: A case report. Current Research in Translational Medicine, 2018, 66, 111-113.	1.2	4
664	Primary myelofibrosis: 2019 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2018, 93, 1551-1560.	2.0	119
665	Ruxolitinib therapy for myelofibrosis in Austria. Wiener Klinische Wochenschrift, 2018, 130, 495-504.	1.0	5
666	Small Molecules in Hematology. Recent Results in Cancer Research, 2018, , .	1.8	6
667	Primary Myelofibrosis. , 2018, , 1125-1150.		0
668	Ruxolitinib. Recent Results in Cancer Research, 2018, 212, 119-132.	1.8	66
669	Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis. International Journal of Molecular Sciences, 2018, 19, 898.	1.8	35
670	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British Journal of Haematology, 2018, 183, 35-46.	1.2	7
671	Sustainedâ€release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis. Hematological Oncology, 2018, 36, 701-708.	0.8	6
672	Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. Blood Advances, 2018, 2, 1980-1984.	2.5	13
673	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâŽ. Seminars in Hematology, 2018, 55, 248-255.	1.8	24
674	Diagnosis and management of prefibrotic myelofibrosis. Expert Review of Hematology, 2018, 11, 537-545.	1.0	13
675	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. Annals of Hematology, 2019, 98, 2319-2328.	0.8	13
676	Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. PLoS ONE, 2019, 14, e0220189.	1.1	3
677	Allogeneic stem cell transplantation for myelofibrosis patients aged â‰¥65 years. European Journal of Haematology, 2019, 103, 370-378.	1.1	11

#	Article	IF	Citations
678	Hematopoietic Cell Transplantation for Myeloproliferative Neoplasms. , 2019, , 173-183.		0
679	Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach. Hematological Oncology, 2019, 37, 424-433.	0.8	3
680	Semiconductor nanomaterials for the detoxification of dyes in real wastewater under visible-light photocatalysis. International Journal of Environmental Analytical Chemistry, 2021, 101, 1735-1749.	1.8	37
681	Reducedâ€intensity conditioning allogeneic transplant with dual Tâ€cell depletion in myelofibrosis. European Journal of Haematology, 2019, 103, 597-606.	1.1	9
682	Primary myelofibrosis: spectrum of imaging features and disease-related complications. Insights Into Imaging, 2019, 10, 71.	1.6	18
683	Post-Myelofibrosis Acute Myeloid Leukemia Effectively Treated with a Combination of Ruxolitinib and 5-Azacytidine. Oncology Research and Treatment, 2019, 42, 532-535.	0.8	2
684	Momelotinib for the treatment of myelofibrosis. Expert Opinion on Pharmacotherapy, 2019, 20, 1943-1951.	0.9	14
685	Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis. Expert Opinion on Orphan Drugs, 2019, 7, 415-425.	0.5	5
686	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer Journal, 2019, 9, 12.	2.8	52
687	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia, 2019, 33, 844-862.	3.3	131
688	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. Haematologica, 2019, 104, 1230-1236.	1.7	12
689	Age at diagnosis is an important prognostic factor in Philadelphiaâ€negative Myeloproliferative Neoplasms. European Journal of Haematology, 2019, 103, 140-141.	1.1	0
690	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. Annals of Hematology, 2019, 98, 1933-1936.	0.8	5
691	Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617Fâ€and MPLW515â€‰Lâ€positive myelofibrosis. Genes Chromosomes and Cancer, 2019, 58, 747-755.	1.5	11
692	Cytogenetic evolution in myeloproliferative neoplasms with different molecular abnormalities. Blood Cells, Molecules, and Diseases, 2019, 77, 120-128.	0.6	0
693	Guideline on myeloproliferative neoplasms: AssociacÃ£o Brasileira de Hematologia, Hemoterapia e Terapia Cellular. Hematology, Transfusion and Cell Therapy, 2019, 41, 1-73.	0.1	3
694	Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. Cancer Medicine, 2019, 8, 2802-2809.	1.3	7
695	MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. Blood Advances, 2019, 3, 83-95.	2.5	51

#	Article	IF	Citations
696	Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?. Current Hematologic Malignancy Reports, 2019, 14, 137-144.	1.2	4
697	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	0.8	3
698	SOHO State of the Art Updates and Next Questions: Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 191-199.	0.2	1
699	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clinic Proceedings, 2019, 94, 599-610.	1.4	103
700	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica, 2019, 104, 659-668.	1.7	56
701	Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 140-145.	0.6	11
702	Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, e204-e208.	2.0	23
703	Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey. Annals of Hematology, 2019, 98, 1119-1125.	0.8	8
704	EDA fibronectinâ€“TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. Journal of Experimental Medicine, 2019, 216, 587-604.	4.2	36
705	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood, 2019, 133, 2233-2242.	0.6	121
706	Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. Blood Advances, 2019, 3, 3196-3200.	2.5	18
707	Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. Blood Advances, 2019, 3, 3700-3708.	2.5	26
708	Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. Hematology Reports, 2019, 11, 8281.	0.3	17
709	Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. Frontiers in Oncology, 2019, 9, 1186.	1.3	142
710	Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis . Cancer Management and Research, 2019, Volume 11, 10777-10790.	0.9	32
711	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. Biology of Blood and Marrow Transplantation, 2019, 25, 932-940.	2.0	25
712	Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. Leukemia Research, 2019, 76, 65-69.	0.4	8
713	WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. Blood Cells, Molecules, and Diseases, 2019, 75, 35-40.	0.6	6

#	Article	IF	Citations
714	EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica, 2019, 104, 947-954.	1.7	33
715	A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1767-1774.	0.6	20
716	Treating early-stage myelofibrosis. Annals of Hematology, 2019, 98, 241-253.	0.8	5
717	Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. American Journal of Hematology, 2019, 94, 87-92.	2.0	18
718	Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis. Annals of Hematology, 2019, 98, 869-879.	0.8	21
719	The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularlyâ€annotated patients with primary myelofibrosis. American Journal of Hematology, 2019, 94, 299-305.	2.0	11
720	20+ Years and alive with primary myelofibrosis: Phenotypic signature of very longâ€lived patients. American Journal of Hematology, 2019, 94, 286-290.	2.0	10
721	The JAK2 46/1 (GGCC) MPNâ€predisposing haplotype: A risky haplotype, after all. American Journal of Hematology, 2019, 94, 283-285.	2.0	3
722	Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leukemia and Lymphoma, 2019, 60, 1036-1042.	0.6	1
723	The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. Bone Marrow Transplantation, 2020, 55, 708-716.	1.3	23
724	Mutational profiling in myelofibrosis: implications for management. International Journal of Hematology, 2020, 111, 192-199.	0.7	9
725	Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia, 2020, 34, 799-810.	3.3	58
726	Myeloproliferative neoplasms. , 2020, , 555-588.		0
727	Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes and Cancer, 2020, 59, 30-39.	1.5	17
728	Systemic Mastocytosis with Associated Primary Myelofibrosis. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 442-443.	0.3	2
729	Myelofibrosis: best practices, controversies and 2019 update. Expert Review of Hematology, 2020, 13, 71-84.	1.0	1
730	A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-Âpolycythemia vera/essential thrombocythemia myelofibrosis (post-ÂPV/ET MF). Leukemia Research, 2020, 88, 106272.	0.4	25
731	Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2020, 38, 1006-1018.	0.8	71

#	Article	IF	Citations
732	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. Medicina ClÃnica (English Edition), 2020, 155, 152-158.	0.1	3
733	HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis. Therapeutic Advances in Hematology, 2020, 11, 204062072093693.	1.1	3
734	Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. Biology of Blood and Marrow Transplantation, 2020, 26, 2252-2261.	2.0	6
735	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer, 2020, 126, 4322-4331.	2.0	19
736	Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Journal of Clinical Medicine, 2020, 9, 2149.	1.0	2
737	The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis. OncoImmunology, 2020, 9, 1782575.	2.1	20
738	The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance. International Journal of Molecular Sciences, 2020, 21, 8885.	1.8	13
739	Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data . OncoTargets and Therapy, 2020, Volume 13, 12367-12382.	1.0	39
740	Genomics of MPN progression. Hematology American Society of Hematology Education Program, 2020, 2020, 440-449.	0.9	10
741	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. Biology of Blood and Marrow Transplantation, 2020, 26, 2237-2244.	2.0	14
742	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Blood Advances, 2020, 4, 3063-3071.	2.5	7
743	Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients. International Journal of Hematology, 2020, 112, 631-639.	0.7	2
744	Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers, 2020, 12, 2194.	1.7	28
745	ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. Blood Cancer Journal, 2020, 10, 99.	2.8	5
746	Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis. Scientific Reports, 2020, 10, 11657.	1.6	17
747	Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. Cancers, 2020, 12, 2250.	1.7	10
748	Non-Pharmacologic Management of Splenomegaly for Patients with Myelofibrosis: Is There Any Role for Splenectomy or Splenic Radiation in 2020?. Current Hematologic Malignancy Reports, 2020, 15, 391-400.	1.2	5
749	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers. Frontiers in Pharmacology, 2020, 11, 604314.	1.6	17

#	Article	IF	Citations
750	Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date . Therapeutics and Clinical Risk Management, 2020, Volume 16, 889-901.	0.9	8
751	Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. Annals of Hematology, 2020, 99, 2555-2564.	0.8	8
752	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	2.5	63
753	Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica, 2020, 105, e221-e224.	1.7	8
754	Prognostic models in the myeloproliferative neoplasms. Blood Reviews, 2020, 42, 100713.	2.8	10
755	Current and future therapies for myelofibrosis. Blood Reviews, 2020, 42, 100715.	2.8	12
756	Genomic ï»¿characterization and prognostication applied to a Brazilian cohort of patients with myelofibrosis. International Journal of Hematology, 2020, 112, 361-368.	0.7	2
757	Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic. Hematology, Transfusion and Cell Therapy, 2020, 42, 195-199.	0.1	1
758	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Annals of Hematology, 2020, 99, 65-72.	0.8	13
759	Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group. JCO Oncology Practice, 2020, 16, 351-359.	1.4	17
760	Myelofibrosis biology and contemporary management. British Journal of Haematology, 2020, 191, 152-170.	1.2	43
761	Management of myelofibrosis after ruxolitinib failure. Annals of Hematology, 2020, 99, 1177-1191.	0.8	62
762	Allogeneic hematopoietic stem-cell transplantation for myelofibrosis. Therapeutic Advances in Hematology, 2020, 11, 204062072090600.	1.1	5
763	Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematological Oncology, 2020, 38, 654-664.	0.8	3
764	Primary analysis of JUMP, a phase 3b, expandedâ€access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. British Journal of Haematology, 2020, 189, 888-903.	1.2	61
765	Selecting patients with primary myelofibrosis for stem cell transplant using clinical, mutational, and transplantâ€specific profiles. Advances in Cell and Gene Therapy, 2020, 3, e80.	0.6	0
766	Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy. Leukemia and Lymphoma, 2020, 61, 1535-1547.	0.6	6
767	Stem cell transplant for the treatment of myelofibrosis. Expert Review of Hematology, 2020, 13, 363-374.	1.0	4

#	Article	IF	Citations
768	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. Biology of Blood and Marrow Transplantation, 2020, 26, 1160-1170.	2.0	9
769	Hematopathology. , 2020, , 1729-2141.		0
770	Management of Myelofibrosis: from Diagnosis to New Target Therapies. Current Treatment Options in Oncology, 2020, 21, 46.	1.3	8
771	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	0.8	15
772	Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica, 2020, 105, e210-e212.	1.7	91
773	A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. Blood Reviews, 2021, 45, 100691.	2.8	17
774	Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia, 2021, 35, 468-475.	3.3	7
775	Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia, 2021, 35, 1-17.	3.3	116
776	Low-dose ruxolitinib shows effective in treating myelofibrosis. Annals of Hematology, 2021, 100, 135-141.	0.8	4
777	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). American Journal of Hematology, 2021, 96, 69-79.	2.0	40
778	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	1.2	19
779	Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leukemia and Lymphoma, 2021, 62, 918-926.	0.6	19
781	Primary myelofibrosis: 2021 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2021, 96, 145-162.	2.0	197
782	European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. Current Research in Translational Medicine, 2021, 69, 103267.	1.2	12
783	National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2020). Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 262-298.	0.1	15
784	Expression profile analysis reveals hub genes that are associated with immune system dysregulation in primary myelofibrosis. Hematology, 2021, 26, 478-490.	0.7	0
785	Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis. Annals of Hematology, 2021, 100, 465-479.	0.8	10
786	Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis. International Journal of Hematology, 2021, 113, 500-507.	0.7	5

#	Article	IF	Citations
787	Myeloproliferative Neoplasms (MPNs). , 2021, , 133-138.		0
788	HSCT in Malignancies. Organ and Tissue Transplantation, 2021, , 99-114.	0.0	0
789	Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematologica, 2021, 144, 484-499.	0.7	26
790	Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression. European Journal of Haematology, 2021, 106, 520-528.	1.1	17
791	Thiotepaâ€“busulfanâ€“fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1593-1602.	1.3	8
792	The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms. International Journal of Molecular Sciences, 2021, 22, 3371.	1.8	5
793	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	2.5	8
794	Impact of Integrated Genetic Information on Diagnosis and Prognostication for Myeloproliferative Neoplasms in the Next-Generation Sequencing Era. Journal of Clinical Medicine, 2021, 10, 1033.	1.0	6
795	Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Advances, 2021, 5, 1442-1451.	2.5	48
796	The role of new technologies in myeloproliferative neoplasms: Application of nextâ€generation sequencing in myelofibrosis. International Journal of Laboratory Hematology, 2021, 43, 1070-1077.	0.7	0
797	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplantation, 2021, 56, 1944-1952.	1.3	7
798	Overview of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 159-176.	0.9	18
800	Advancing Effective Clinical Trial Designs for Myelofibrosis. Hematology/Oncology Clinics of North America, 2021, 35, 431-444.	0.9	2
801	The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry. Current Oncology, 2021, 28, 1544-1557.	0.9	6
803	Application of Stem Cell Therapy in Myelofibrosis. Hematology/Oncology Clinics of North America, 2021, 35, 391-407.	0.9	6
804	Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 177-189.	0.9	14
805	Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 318-327.e6.	0.2	11
806	Dipeptidylâ€peptidase 4 inhibitor increased and maintained platelet count in a patient with primary myelofibrosis. EJHaem, 2021, 2, 551-554.	0.4	0

#	Article	IF	Citations
807	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia, 2021, 35, 3455-3465.	3.3	25
808	Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021. Frontiers in Immunology, 2021, 12, 637512.	2.2	9
809	Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia, 2021, 35, 3551-3560.	3.3	40
810	Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands. HemaSphere, 2021, 5, e595.	1.2	1
811	Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e551-e558.	0.2	3
812	Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e569-e578.	0.2	2
813	Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. British Journal of Haematology, 2021, 194, 557-567.	1.2	6
814	Effect of preâ€transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. European Journal of Haematology, 2021, 107, 517-528.	1.1	2
815	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of <scp>EBMT</scp> and the Spanish Myelofibrosis Registry. American Journal of Hematology, 2021, 96, 1186-1194.	2.0	17
816	Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. Blood Cancer Journal, 2021, 11, 135.	2.8	19
817	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System lowâ€, intermediateâ€1â€, intermediateâ€2â€, and highâ€risk myelofibrosis in JUMP, a Phase 3b, expandedâ€access study. Hematological Oncology, 2021, 39, 558-566.	0.8	11
818	Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions. Expert Review of Hematology, 2021, 14, 607-619.	1.0	4
819	The JAKâ€“STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. European Heart Journal, 2021, 42, 4389-4400.	1.0	61
820	Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 2021, 10, 1962.	1.8	11
821	The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. Medicina (Lithuania), 2021, 57, 813.	0.8	2
822	Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes. Genes, 2021, 12, 1271.	1.0	4
823	Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis. Sultan Qaboos University Medical Journal, 0, , .	0.3	0
824	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. American Journal of Hematology, 2021, 96, 1472-1480.	2.0	20

#	Article	IF	Citations
825	CAMK2G is identified as a novel therapeutic target for myelofibrosis. Blood Advances, 2021, , .	2.5	2
826	Evolution in Prognostication in Myelofibrosis: From IPSS and DIPSS to MIPSS-70 and MYSEC-PM. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S125-S126.	0.2	0
827	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 2021, 13, 4744.	1.7	9
828	The Role of Navitoclax in Myelofibrosis. Cureus, 2021, 13, e17976.	0.2	0
829	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosisâ€"A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2021, 27, 873.e1-873.e13.	0.6	9
830	The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. Korean Journal of Internal Medicine, 2021, 36, 45-62.	0.7	13
831	Current View on Diagnosis and Treatment of Classical Ph-Negative Myeloproliferative Neoplasms. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 129-137.	0.1	4
832	Outcomes of Bone Marrow Transplantation. Organ and Tissue Transplantation, 2021, , 689-730.	0.0	0
833	Neoplastische BildungsstÃ¶rungen der HÃmatopoiese mit erhaltener Ausreifung. , 2019, , 47-87.		2
834	Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment. Cancer Chemotherapy and Pharmacology, 2020, 85, 1109-1117.	1.1	5
835	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews, 2020, 42, 100706.	2.8	54
836	CaracterÃsticas clÃnico-biolÃ³gicas de los pacientes con mielofibrosis: un anÃ¡lisis de 1.000 casos del Registro EspaÃ±ol de Mielofibrosis. Medicina ClÃnica, 2020, 155, 152-158.	0.3	3
837	The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis. Journal of Clinical Pathology, 2018, 71, 514-521.	1.0	3
838	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight, 2020, 5, .	2.3	18
839	Is there a role for the use of IFN-Î± in primary myelofibrosis?. Hematology American Society of Hematology Education Program, 2012, 2012, 567-570.	0.9	9
840	MPL W515â€‰L/K mutations in myeloproliferative neoplasms. Egyptian Journal of Medical Human Genetics, 2019, 20, .	0.5	3
841	JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis. PLoS ONE, 2013, 8, e59791.	1.1	15
842	Therapeutic Advances in Myeloproliferative Neoplasms: The Role of New-Small Molecule Inhibitors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 406-410.	1.8	3

#	Article	IF	Citations
843	Classification of Myeloproliferative Neoplasms and Prognostic Factors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 419-424.	1.8	2
844	Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone. Acta Medica (Hradec Kralove), 2016, 59, 50-53.	0.2	4
845	Acquired Î²-Thalassemia as an Etiology of Microcytic Anemia in Primary Myelofibrosis. Journal of Hematology (Brossard, Quebec), 2015, 4, 148-150.	0.4	1
846	A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis. Tomography, 2016, 2, 67-78.	0.8	13
847	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget, 2017, 8, 79073-79086.	0.8	63
848	MPL W515L expression induces TGFÎ² secretion and leads to an increase in chemokinesis via phosphorylation of THOC5. Oncotarget, 2016, 7, 10739-10755.	0.8	7
849	Platelet expression of PKCepsilon oncoprotein in myelofibrosis is associated with disease severity and thrombotic risk. Annals of Translational Medicine, 2017, 5, 273-273.	0.7	10
850	Biology of Myeloproliferative Malignancies. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 314-325.	0.1	10
851	Myelofibrosis Models: Literature Review and Own Data. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 75-84.	0.1	2
852	Elevated Neutrophilâ€“toâ€“Lymphocyte-ratio and Plateletâ€“toâ€“Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself?. Anticancer Research, 2018, 38, 3157-3163.	0.5	16
853	The Indications for Allogeneic Stem Cell Transplantation in Myeloid Malignancies. Deutsches Ärzteblatt International, 2015, 112, 262-70.	0.6	14
854	Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. F1000 Medicine Reports, 2010, 2, .	2.9	3
855	JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling. Journal of Health Economics and Outcomes Research, 2020, 7, 61-70.	0.6	4
858	Cytodiagnosis of extramedullary hematopoiesis in serous effusion: A rare presentation unfolding the underlying etiology. CytoJournal, 2018, 15, 18.	0.8	2
859	Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 503.	0.1	1
860	Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report. Turkish Journal of Haematology, 2015, 32, 180-183.	0.2	4
861	Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2017, 34, 27-33.	0.2	10
862	Philadelphia-negative chronic myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 140-149.	0.7	14

#	Article	IF	Citations
863	Myeloproliferative neoplasms (MPNs) â€“ Part 1: An overview of the diagnosis and treatment of the â€œclassicalâ€•MPNs. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2018, 28, 262-268.	0.1	11
864	Long-Term Survival in the Concomitant Evolution of Two Cancers: The Idiopathic Myelofibrosis and the Clear Cell Renal Carcinoma; A Case Report. Iranian Red Crescent Medical Journal, 2019, In Press, .	0.5	1
865	Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. Clinics, 2013, 68, 339-343.	0.6	9
866	Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5013-5018.	0.5	25
867	A populationâ€based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: Comparison with data from a Mayo Clinic single institutional series. American Journal of Hematology, 2021, 96, E464-E468.	2.0	9
868	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Annals of Hematology, 2022, 101, 131-137.	0.8	20
869	Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leukemia and Lymphoma, 2022, 63, 694-702.	0.6	22
870	New Markers of Disease Progression in Myelofibrosis. Cancers, 2021, 13, 5324.	1.7	6
871	Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms. Cancers, 2021, 13, 5035.	1.7	1
872	Factors affecting prognosis in myelofibrosis. F1000 Medicine Reports, 2009, 1, .	2.9	0
873	Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes. , 2010, , 155-176.		0
874	JAK Inhibitors in Myeloproliferative Neoplasms. , 2010, 7, .		2
875	Cytogenetic Findings in Classical MPNs. , 2011, , 69-83.		0
876	Hematopoietic Cell Transplantation for Myelofibrosis. , 2011, , 139-150.		0
877	Prognostic Factors in Classic Myeloproliferative Neoplasms. , 2011, , 85-96.		0
878	JAK2 Inhibitors for Therapy of Myeloproliferative Neoplasms. , 2011, , 151-167.		0
879	Traitement des syndromes myÃ©loprolifÃ©ratifs Philadelphie-nÃ©gatifs. , 2011, , 769-777.		0
881	HÃmatologische und onkologische Erkrankungen. , 2011, , 607-718.		0

#	Article	IF	Citations
884	Current Clinical Needs. , 2012, , 149-161.		0
885	Risk Stratification in PMF. , 2012, , 163-175.		0
886	A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy. , 2012, , 203-214.		0
887	Do We Need Biological Studies for Patient Management?. , 2012, , 11-16.		0
888	Patientâ€™s Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms. , 2012, , 47-55.		0
889	Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms. , 2012, , 131-145.		0
890	Ongoing Clinical Trials in Myeloproliferative Neoplasms. , 2012, , 215-232.		0
891	Nontransplant Treatment Options for Myelofibrosis: How to Treat Anemia, Splenomegaly, Constitutional Symptoms, and Extramedullary Disease. , 2012, , 177-186.		0
892	Chronic Myeloproliferative Disorders:From Molecular Pathogenesis to Targeted Therapy. , 2012, , 241-276.		0
893	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
894	FDA Approval of the JAK Inhibitor Ruxolitinib and the Management of Patients with Myelofibrosis. , 2012, 9, .		0
895	Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis. Journal of Hematopoietic Cell Transplantation, 2012, 1, 15-23.	0.1	0
896	The role of allogeneic stem cell transplantation in primary myelofibrosis. , 2013, , 65-71.		0
897	Avances farmacolÃ³gicos en mielofibrosis. , 2013, , 59-64.		0
899	CD133 Marks a Stem Cell Population That Drives Human Primary Myelofibrosis. Blood, 2013, 122, 1601-1601.	0.6	0
900	The Discovery and Development of Ruxolitinib for the Treatment of Myelofibrosis. RSC Drug Discovery Series, 2014, , 419-439.	0.2	0
901	Myeloproliferative Neoplasms â€“ Molecular Biology and Potential Targets for Intervention. , 2014, , 62-102.		0
902	Myeloproliferative Erkrankungen. , 2015, , 1-11.		0

#	Article	IF	Citations
903	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
910	Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs). Hematology American Society of Hematology Education Program, 2015, 2015, 649-651.	0.9	0
911	Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 279-286.	0.1	1
912	Evolution of Myelofibrosis Treatment. Korean Journal of Medicine, 2016, 90, 293-297.	0.1	0
914	The Symptom Management of Myeloproliferative Neoplasms. Advances in Clinical Medicine, 2017, 07, 59-65.	0.0	0
915	Targeted Therapy of Myelofibrosis. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2017, 10, 471-478.	0.1	4
917	Myeloproliferative Neoplasms. , 2019, , 569-578.		1
918	Znaczenie badaÅ„ molekularnych dla oceny ryzyka i rokowania u chorych na pierwotne wÅ‚Ã³knienie szpiku w oparciu o wskaÅºniki prognostyczne IPSS, DIPSS oraz MIPSS. Acta Haematologica Polonica, 2018, 49, 140-146.	0.1	0
919	7. Diagnosis and Treatment of Chronic Myeloid Leukemia and Myeloproliferative Neoplasms. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 547-550.	0.0	0
920	A Case of Myelofibrosis Complicated Acquired Von Willebrand Syndrome. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1448-1453.	0.0	0
921	Standard care and investigational drugs in the treatment of myelofibrosis. Drugs in Context, 2019, 8, 1-16.	1.0	4
923	Primary myelofibrosis. , 2020, , 5247-5253.		0
924	Miyelofibrozisli olgularda allojenik kÃ¶k hÃ¼cre nakil sonuÃ§larÄ±mÄ±z: tek merkezli, retrospektif bir analiz. Ege TÄ±p Dergisi, 0, , 109-112.	0.1	0
925	Bleeding complications in bcrâ€ablâ€negative myeloproliferative neoplasms (MPN): A retrospective singleâ€center study of 829 MPN patients. European Journal of Haematology, 2022, 108, 154-162.	1.1	6
926	HSCT in Malignancies. Organ and Tissue Transplantation, 2020, , 1-16.	0.0	0
927	Outcomes of Bone Marrow Transplantation. Organ and Tissue Transplantation, 2020, , 1-43.	0.0	0
929	Myelofibrozis hastalarÄ±nda Ruxolitinib kullanÄ±mÄ±: tek merkez deneyimi ve JAK-2 allel yÃ¼kÃ¼ ile Ruxolitinib yanÄ±tÄ± arasÄ±ndaki iliÅŸki. Pamukkale Medical Journal, 0, , .	0.2	0
930	Myeloproliferative Neoplasms: Emerging Treatment Options for Myelofibrosis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1788-1791.	2.3	1

#	Article	IF	Citations
931	Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies. International Review of Cell and Molecular Biology, 2021, 365, 97-116.	1.6	6
932	Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities. International Review of Cell and Molecular Biology, 2021, 365, 1-69.	1.6	13
933	HÃmatologische und onkologische Erkrankungen. , 2020, , 329-335.		0
934	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
935	Multi-focal Lytic Lesions in a Patient with Myelofibrosis: A Case Report. Cureus, 2020, 12, e7475.	0.2	3
936	Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models. Leukemia, 2022, 36, 746-759.	3.3	10
937	Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 â€“) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 2022, 22, 336-346.	0.2	5
938	Progression in Ph-Chromosome-Negative Myeloproliferative Neoplasms: An Overview on Pathologic Issues and Molecular Determinants. Cancers, 2021, 13, 5531.	1.7	3
942	Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica, 2021, 106, 3162-3169.	1.7	4
943	Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Management and Research, 2010, 2, 219-23.	0.9	2
944	Emerging therapeutic options for myelofibrosis: a Canadian perspective. American Journal of Blood Research, 2012, 2, 170-86.	0.6	3
945	Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. American Health and Drug Benefits, 2013, 6, 264-74.	0.5	37
946	Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors. Journal of the Advanced Practitioner in Oncology, 2015, 6, 532-50.	0.2	0
951	Ph-negative myeloproliferative Neoplasien. , 2022, , 212-220.		0
952	VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. TH Open, 2021, 05, e513-e520.	0.7	1
953	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances, 2022, 6, 373-375.	2.5	34
954	Novel strategies for challenging scenarios encountered in managing myelofibrosis. Leukemia and Lymphoma, 2021, , 1-15.	0.6	1
955	Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia. Cancer Causes and Control, 2022, 33, 343-351.	0.8	0

#	Article	IF	Citations
956	A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1271-1278.	2.3	5
957	Momelotinib: an emerging treatment for myelofibrosis patients with anemia. Journal of Hematology and Oncology, 2022, 15, 7.	6.9	36
958	Optimal Timing of Allogeneic Stem Cell Transplantation for Primary Myelofibrosis. Transplantation and Cellular Therapy, 2022, 28, 189-194.	0.6	5
959	Improved survival of patients with myelofibrosis in the last decade: Singleâ€center experience. Cancer, 2022, , .	2.0	16
960	Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms. International Journal of Molecular Sciences, 2022, 23, 1013.	1.8	8
961	Allogeneic Stem Cell Transplantation Combined With Transfusion of Mesenchymal Stem Cells in Primary Myelofibrosis: A Multicenter Retrospective Study. Frontiers in Oncology, 2021, 11, 792142.	1.3	2
962	Reduced intensity hematopoietic stem cell transplantation forÂaccelerated-phase myelofibrosis. Blood Advances, 2022, 6, 1222-1231.	2.5	20
963	How I Diagnose Primary Myelofibrosis. American Journal of Clinical Pathology, 2022, 157, 518-530.	0.4	3
964	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUXâ€IOL study. British Journal of Haematology, 2022, 197, 190-200.	1.2	7
965	Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e532-e540.	0.2	3
966	A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Advances, 2022, 6, 1855-1864.	2.5	47
967	How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. Cells, 2022, 11, 553.	1.8	5
968	Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. Hematology, 2022, 27, 23-31.	0.7	6
969	A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study. Therapeutic Advances in Hematology, 2022, 13, 204062072210844.	1.1	2
970	Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms. Journal of Personalized Medicine, 2022, 12, 364.	1.1	8
971	Novel treatments for myelofibrosis: beyond JAK inhibitors. International Journal of Hematology, 2022, 115, 645-658.	0.7	5
972	Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm. Blood Research, 2022, 57, 59-68.	0.5	7
973	Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American Journal of Hematology, 2022, 97, 846-855.	2.0	9

#	Article	IF	Citations
974	Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience. Journal of Hematopathology, 0, , 1.	0.2	0
975	How myeloproliferative neoplasms patientsâ€™ experience and expectations differ from physiciansâ€™: the international MPN Landmark survey. Korean Journal of Internal Medicine, 2022, 37, 444-454.	0.7	2
976	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronicâ€phase myelofibrosis. Cancer, 2022, 128, 2449-2454.	2.0	7
977	Characterization of Glycoproteoforms of Integrins Î±2 and Î²1 in Megakaryocytes in the Occurrence of JAK2V617F Mutation-Induced Primary Myelofibrosis. Molecular and Cellular Proteomics, 2022, 21, 100213.	2.5	1
978	Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis. Cancers, 2022, 14, 1799.	1.7	0
979	Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. Cancer Research, 2022, 82, 749-763.	0.4	20
980	Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?. Hematology American Society of Hematology Education Program, 2021, 2021, 453-462.	0.9	7
981	IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis. Experimental Hematology and Oncology, 2021, 10, 58.	2.0	3
982	Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives. Cells, 2021, 10, 3551.	1.8	24
983	Real-life ruxolitinib experience in intermediate-risk myelofibrosis. Blood Research, 2021, 56, 322-331.	0.5	4
984	Patient-specific comorbidities as prognostic variables for survival inÂmyelofibrosis. Blood Advances, 2023, 7, 756-767.	2.5	6
985	Improving allogeneic stem cell transplantation in myelofibrosis. International Journal of Hematology, 2022, 115, 619.	0.7	3
986	Bone marrow. , 0, , 813-942.		0
987	Myeloproliferative neoplasms. , 0, , 141-154.		0
992	Is there a role for the use of IFN-Î± in primary myelofibrosis?. Hematology American Society of Hematology Education Program, 2012, 2012, 567-70.	0.9	4
993	Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Management and Research, 2010, 2, 219.	0.9	3
999	Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms. Internal Medicine, 2022, 61, 3483-3490.	0.3	2
1000	Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers, 2022, 14, 2331.	1.7	2

#	Article	IF	Citations
1001	The odyssey of pacritinib in myelofibrosis. Blood Advances, 2022, 6, 4905-4913.	2.5	14
1002	Momelotinib for the treatment of myelofibrosis with anemia. Future Oncology, 2022, 18, 2559-2571.	1.1	8
1004	Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis. Expert Review of Hematology, 0, , 1-9.	1.0	0
1005	Survival and risk of vascular complications in myelofibrosisâ€"A ‹scp›populationâ€based‹/scp› study from the Swedish ‹scp›MPN‹/scp› group. European Journal of Haematology, 2022, 109, 336-342.	1.1	2
1006	Advances in the Study of High-Risk Gene Mutations for Primary Myelofibrosis. Journal of Biosciences and Medicines, 2022, 10, 76-82.	0.1	0
1007	Hematopoietic stem cell transplantation for myeloproliferative neoplasms. Journal of Illusion, 2022, 11, 148-160.	0.0	0
1008	Targeting the PI3K pathway in myeloproliferative neoplasms. Expert Review of Anticancer Therapy, 2022, 22, 835-843.	1.1	7
1009	Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	0
1010	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology, 2022, 29, 4970-4980.	0.9	2
1011	Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis â€“ an option beyond ruxolitinib. Expert Review of Hematology, 2022, 15, 583-595.	1.0	4
1012	Impact of molecular profiling on the management of patients with myelofibrosis. Cancer Treatment Reviews, 2022, 109, 102435.	3.4	2
1013	Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia, 2022, 36, 2261-2268.	3.3	26
1014	Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant. Blood Cancer Journal, 2022, 12, .	2.8	0
1015	Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Review of Hematology, 2022, 15, 671-684.	1.0	20
1016	A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis. HemaSphere, 2022, 6, e757.	1.2	2
1017	Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis. Blood Cancer Journal, 2022, 12, .	2.8	8
1018	Considerations to comprehensive care for the older individual with myelofibrosis. Best Practice and Research in Clinical Haematology, 2022, 35, 101371.	0.7	0
1019	Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors. Current Opinion in Oncology, 2022, 34, 729-737.	1.1	0

#	Article	IF	Citations
1020	Transplantation algorithm for myelofibrosis in 2022 and beyond. Best Practice and Research in Clinical Haematology, 2022, 35, 101369.	0.7	2
1021	EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S65-S66.	0.2	0
1022	Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2022, 17, 127-139.	1.2	5
1023	Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma. Targeted Oncology, 2022, 17, 517-527.	1.7	9
1024	Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients. Cancers, 2022, 14, 4485.	1.7	2
1025	Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 1033-1062.	2.3	42
1026	Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital. Journal of Blood Medicine, 0, Volume 13, 495-503.	0.7	0
1027	Coexistence of Post-essential Thrombocythemia Myelofibrosis With Monoclonal Gammopathy of Undetermined Significance: A Case Report. Cureus, 2022, , .	0.2	0
1028	Prognostic Role of Cell Blood Count in Chronic Myeloid Neoplasm and Acute Myeloid Leukemia and Its Possible Implications in Hematopoietic Stem Cell Transplantation. Diagnostics, 2022, 12, 2493.	1.3	1
1029	Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study. Leukemia and Lymphoma, 0, , 1-16.	0.6	0
1030	Analysis of Predictive Factors for Early Response to Ruxolitinib in 320 Patients with Myelofibrosis From the Polish Adult Leukemia Group (PALG) Registry. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, e19-e26.	0.2	1
1031	Trend of circulating CD34⁺ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment. British Journal of Haematology, 2023, 200, 315-322.	1.2	4
1032	Anemia in myelofibrosis: Current and emerging treatment options. Critical Reviews in Oncology/Hematology, 2022, 180, 103862.	2.0	11
1033	Resolution of the Expert Council on the issues of diagnosis and treatment of myeloproliferative neoplasms, existing standards and the possibility of their implementation in real clinical practice in Russia. Oncogematologiya, 2022, 17, 60-66.	0.1	0
1034	Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematology,the, 2023, 10, e59-e70.	2.2	10
1035	BOREAS: aÂglobal, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Future Oncology, 2022, 18, 4059-4069.	1.1	10
1036	Biological drivers of clinical phenotype in myelofibrosis. Leukemia, 2023, 37, 255-264.	3.3	14
1037	Myelofibrosis. Blood, 2023, 141, 1954-1970.	0.6	20

#	Article	IF	Citations
1038	Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting. Journal of Clinical Medicine, 2022, 11, 7418.	1.0	8
1039	Biosimilar erythropoiesisâ€stimulating agents are an effective and safe option for the management of myelofibrosisâ€related anemia. European Journal of Haematology, 0, , .	1.1	0
1040	Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis. HemaSphere, 2023, 7, e818.	1.2	11
1041	Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients. Journal of Clinical Medicine, 2023, 12, 578.	1.0	8
1042	Trends in overall mortality among US veterans with primary myelofibrosis. BMC Cancer, 2023, 23, .	1.1	0
1043	Refining patientsâ€™ care in myelofibrosis: looking at second primary malignancies. Leukemia and Lymphoma, 0, , 1-2.	0.6	0
1044	Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies. Journal of Hematology (Brossard, Quebec), 2022, 11, 197-209.	0.4	3
1045	Primary myelofibrosis: 2023 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2023, 98, 801-821.	2.0	53
1046	Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm. Blood Research, 2023, 58, 42-50.	0.5	1
1047	Characterizing the Bone Marrow Environment in Advanced-Stage Myelofibrosis during Ruxolitinib Treatment Using PET/CT and MRI: A Pilot Study. Tomography, 2023, 9, 459-474.	0.8	0
1048	Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future. Journal of Clinical Medicine, 2023, 12, 2188.	1.0	10
1049	Prognostication in myeloproliferative neoplasms, including mutational abnormalities. Blood Research, 2023, 58, S37-S45.	0.5	1
1050	Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center. Balkan Medical Journal, 0, , .	0.3	0
1051	Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the <scp>SIMPLIFY</scp> phase <scp>III</scp> studies. Cancer Medicine, 2023, 12, 10612-10624.	1.3	6
1052	Cytopenic myelofibrosis: prevalence, relevance, and treatment. Expert Opinion on Pharmacotherapy, 2023, 24, 901-912.	0.9	2
1062	Allogeneic Cell Transplantation for Myeloproliferative Neoplasms. , 2024, , 279-286.		0
1067	Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model. Blood Cancer Journal, 2023, 13, .	2.8	6
1082	Prognostic Models for Primary and Secondary Myelofibrosis. , 2023, , 539-541.		0

#	Article	IF	Citations
1083	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: When and How?. , 2023, , 577-583.		0
1085	Molecular testing in myeloproliferative neoplasms. , 2024, , 569-587.		1